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ABSTRACT OF THE DISSERTATION
A Novel Function of Plasmacytoid Dendritic Cells in Regulating Type 2 Immune Responses
by
Hannah Leigh Miller
Doctor of Philosophy in Biology and Biomedical Sciences
Immunology
Washington University in St. Louis, 2021
Professor Marco Colonna, Chair
The generation of an allergic response is particularly perplexing, as the mucosal immune
system is exposed to a myriad of antigens on a daily basis, the majority of which do not elicit
inflammation. However, for the growing population of patients impacted by allergic diseases,
there is a clear breakdown of normal tolerance to innocuous antigens, resulting in symptoms
mediated by antigen specific T helper 2 (Th2) cells. In addition to their well-established role in
early antiviral immunity via production of type I interferon, plasmacytoid dendritic cells (pDC)
have been implicated in the generation of immune tolerance in a variety of settings.
Furthermore, evidence suggests that pDC limit chronic type 2 immunopathology that can follow
respiratory viral infections. Thus, we hypothesized that pDC may play a role in suppressing the
development of Th2 effector cells.
According to previous studies, pDC can have very disparate effects on naïve CD4+ T cell
differentiation, with reports showing that pDC prime Th1, Th2, and T regulatory cells. Lacking
from our current knowledge is how pDC behave in situ, as many findings rely on data generated
in vitro or with adoptive transfer strategies. The current paradigm suggests that differential
priming of Th1, Th2 or tolerogenic T cells depends on cell surface and soluble signals that pDCs
ix

provide to CD4+ T cells together with peptide-MHCII complex, despite our growing
understanding that pDC are poor antigen presenters compared to their conventional DC
counterparts. To understand how pDC influence CD4+ T cell polarization in vivo, we used the
CLEC4C-DTR transgenic mice, previously generated in our laboratory, which allow for specific
and transient depletion of pDC. We found that pDC suppressed a model of Th2-driven
cutaneous contact hypersensitivity (CHS) but did not impact a Th1-driven CHS model. PDC
depletion skewed CD4+ T cells towards a Th2 phenotype and limited Th1 polarization, through a
mechanism independent of the canonical pDC-derived effectors, type I interferon, type III
interferon, and IL-12. Instead, pDC shaped T cell polarization indirectly by altering the balance
of migratory cDC subsets in the lymph node. pDC-depleted mice had increased Th2/Th17priming IRF4+ cDC2 and fewer Th1-priming CD103+ IRF8+ cDC1. Single cell RNA-sequencing
analysis also revealed that pDC-depleted mice had an expansion of non-canonical CX3CR1+
DC, which shared features with both pDC and DC2. Our results suggest a novel model in which
pDC can influence T cell polarization by controlling the balance of cDC subsets within the
lymph node during T cell priming. This novel function of pDC undoubtedly contributes to the
ability of pDC to suppress allergic pathology and defines new therapeutic approaches to help
patients afflicted with allergic and atopic disease.
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Chapter 1

Plasmacytoid dendritic cells have diverse functions in
immunity and immunopathology
Hannah Miller
Department of Pathology and Immunology, Washington University School of Medicine

1.1 Abstract
Plasmacytoid dendritic cells were first described as a distinct cell type with unusual morphology
in the late 1950s, but it was not until 40 years later they were definitively identified as the
professional type 1 interferon (IFN-I) producers that they are known as today1,2. Although most
cells are capable of producing IFN-I, pDC have specialized intracellular machinery that
facilitates production extremely quickly and robustly, making 100-1,000 times more IFN-I on a
per cell basis2. pDC are also capable of making type III interferons (IFN-λ), TNF-α, IL-6, IL-12,
and many chemokines (CCL3, CCL4, CXCL9, and CXCL10)3,4. As a member of the dendritic
cell family, they also express MHCII and are capable of presenting antigen to CD4+ T cells5.
With these many disparate functions, pDC have been implicated in a variety of immune
processes, including anti-viral responses, induction of immunological tolerance, and
autoimmunity3,6. Here we will review the multifaceted physiologic and pathologic biology of
pDC.
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1.2 pDC have unique phenotypic characteristics and trafficking
patterns compared to conventional dendritic cells (cDC).
The characterization of cell surface markers expressed by pDC in human and mouse has been
rather extensive and has revealed clear fundamental differences between pDC and conventional
DC (cDC). Human pDC can be distinguished from other cell types by their expression of the Ctype lectin BDCA2 (gene name CLEC4C) and the immunoglobulin superfamily receptor
immunoglobulin-like transcript 7 (ILT7, also known as LILRA4). Human pDC also express
ILT3 (LILRB4), CD4, CD68, and the IL-3-receptor α subunit (CD123). IL-3 has been shown to
promote the survival of human pDC in vitro7. Human pDC express cell adhesion molecule CD2
in a bimodal fashion and CD2+ pDC have been shown to produce lysozyme8, suggesting an antibacterial function, although this has not been definitely proven. In addition, human pDC express
granzyme B9 as well as the high affinity Fcε-receptor α chain (FcεRα)10.

Human pDC lack

expression of CD11c, as well as other lineage-defining markers such as CD3, CD14, CD16, and
CD193.

Unlike human pDC, mouse pDC express intermediate levels of CD11c, and are often identified
using this molecule in combination with B220 and siaclic acid-binding immunoglobulin-like
lectin H (Siglec-H). Siglec-H is fairly specific for mouse pDC, although macrophage subsets in
the spleen, lymph node, and brain do express Siglec-H, and some progenitors in the bone marrow
express Siglech mRNA11,12. Notably, these macrophage populations are not typically liberated in
cell preparations from the secondary lymphoid organs, so it is generally accepted that all SiglecH+ cells within the preparations are pDC. Mouse pDC also express Ly6C and bone marrow
stromal antigen 2 (BST-2), but these markers can be expressed on other cell types especially in
settings of inflammation13. Like human pDC, mouse pDC also express CD4 and express CD8α
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in a bimodal distribution. Additionally, most pDC in the periphery express Ly49Q (Klra17),
CCR9, and SCA-1, but in the bone marrow these markers indicate different stages of
differentiation3,4.

In addition to differing in cell surface markers, pDC have notably different morphology and
trafficking patterns compared to cDC.

PDC were originally thought to be a subset of

lymphocytes due to their expression of CD4 and their plasma cell-like morphology, with the
presence of a large endoplasmic reticulum that suggested a secretory function. PDC from blood
or secondary lymphoid organs to not display the cell membrane protrusions or extensive
cytoplasm that characterize cDC, but can develop this morphology upon activation with IL-3 and
CD40L14,15.

CDC have trafficking patterns that are consistent with their essential role of priming naïve T
cells in settings of inflammation and promoting T cell tolerance under homeostatic conditions.
Precursors of cDC leave the bone marrow, enter circulation, and seed peripheral tissues and
secondary lymphoid organs, where they develop into migratory and resident cDC, respectively.
These immature cDC remain capable of continually sampling the tissue antigen milieu and have
a low basal level of antigen processing and presentation on MHCII molecules, with low levels of
costimulatory molecules5,16. At steady state, migratory DC within the tissue continually traffic
through afferent lymphatics to the lymph node where they promote T cell tolerance to self
antigens17,18. This process requires interactions between CCR7 on cDC and CCL21 present on
lymphatic vessels19.

During this process they complete maturation, while the resident cDC

remain immature until they encounter activation signals via TLRs or other pattern recognition
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receptors. With inflammation, trafficking of migratory DC increases and all cDC cease antigen
sampling while upregulating costimulatory molecules and retaining high levels of
peptide:MHCII complex on the surface. This behavior is consistent with the ability of cDC to
find the rare naïve T cell that will recognize the peptide being presented16.

Conversely, pDC complete maturation in the bone marrow and exit into the blood stream.
Retention within the bone marrow niche is dependent on CXCR4, while egress from the bone
marrow is mediated by CCR2 and CCR520,21. PDC enter lymph nodes via the high endothelial
venules in a manner similar to lymphocytes, mediated by CD62L, PSLG-1, CXCR4, and CCR7.
Trafficking to the splenic white pulp via the central arteriole is dependent on CCR7 and
CXCR422. Unlike cDC, pDC do not seem to traffic to all peripheral tissues during the steady
state. PDC are largely absent from the skin and lungs during homeostasis, however, they are
found in the liver, thymus and gut. CCR9 mediates trafficking to the thymus and the small
intestine, while CCR9 is dispensible for pDC trafficking to the colon23–25. PDC within the gut
are largely confined to the intraepithelial compartment, which is facilitated by expression of both
mucosal addressin cell adhesion molecule 1 (MADCAM1) and β7 integrin26. The mechanisms
of pDC trafficking to the liver are not well defined.

While they are absent from many peripheral tissues at steady state, it has long been appreciated
that pDC robustly infiltrate diverse sites of pathology. In fact, one of the pioneer studies on pDC
identified them as infiltrates of inflamed tonsil tissue1. PDC are recruited to the skin in lupus
erythematosus, lichen planus, contact dermatitis, psoriasis, and are robustly recruited to human
or mouse skin treated with imiquimod (a TLR7 agonist)20,27,28. They are recruited to the lungs
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during RSV infection, and the skin draining lymph nodes of mice infected with Leishmania
major or HSV-129,30. They are also found in robust numbers in the lymph nodes of patients
infected with mycobacterium4.

Fascinatingly, even when pDC accumulate in the draining

lymph nodes of mucosal sites of inflammation, it appears that these cells enter via the HEV,
rather than trafficking from the inflamed site through the lymphatics. During inflammation,
lymph node homing via the HEV involves E-selectin, CCR5 and CXCR320,31. PDC migration to
inflamed tissue is mediated by C3aR, C5aR, adenosine receptor 1 (A1), and chemerin receptor
23 (ChemR23), in addition to some chemokine receptors that mediate physiologic trafficking
such as CCR2, CXCR4, CCR6 and CCR103,20.

1.3 pDC are developmentally distinct from cDC.
The literature indicates that both cDC and pDC can arise from a common DC progenitor
(CDP)32,33. The CDP is thought to arise from the common myeloid progenitor (CMP) via the
macrophage/dendritic cell progenitor (MDP), which generates macrophages and dendritic cells
exclusively. The CDP produces cDC1, cDC2, and pDC, and clonogenic progenitors for each of
these DC subsets have been of intense interest to the field, as this would allow for better
identification of DC subsets in human and mouse as well as the development of genetic tools to
assess the functionality of these cells. Committed progenitors that arise from the CDP have been
identified, and transcriptional mechanisms by which these cells exclude other fates and maintain
lineage commitment have been identified for cDC134–36, but are still under investigation for
cDC2 and pDC37. Interestingly, two recent studies have elegantly described the transcriptional
mechanisms that lead to emergence of a pre-DC1 progenitor from the CDP35,36. These studies
demonstrate that a +41kB enhancer of IRF8, previously thought to only be active in pDC, is also
important during cDC1 development. IRF8 expression is essential for cDC1 development38,39,
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and the absence of this enhancer results in loss of cDC1 specification from the CDP and in loss
of the mature cDC1. Chip-Seq data from B cells suggests that this enhancer is likely bound by
E-proteins, which are required for both cDC1 and pDC development. Collectively, this data
suggests that cDC1 and pDC could share a developmental stage in which the +41kB enhancer of
IRF8 is accessible and E-proteins are active36.

Like the function and identify of pDC themselves, the developmental pathways that produce
pDC have also been particularly enigmatic. Although the myeloid pathway has been considered
the major producer of pDC, the literature also suggests that pDC can develop from the common
lymphoid progenitor6,40,41. This developmental pathway has received renewed interest as of late,
and studies have emerged that propose the lymphoid pathway is the major developmental
pathway by which pDC are produced in the bone marrow42,43.

Early reports of the pDC

progenitor identified it as lacking lineage markers (LIN-), macrophage colony stimulating factor
(CSF1R/CD115), and IL7RA (CD127), and expressing low to intermediate receptor tyrosine
kinase KIT (SCFR/CD117) and Fms-like tyrosine kinase 3 (FLT3/CD135). This progenitor
could arise from the CDP (LIN-FLT3+CD115+CD117int) or the IL7RA+ lymphoid-primed
multipotent progenitor (LMPP)40. Likely downstream, a CCR9- pDC progenitor was described
prior to the aforementioned study that expresses Siglec-H, CD11c, and B220, but lacks MHCII.
This cell gives rise to the CCR9+ mature pDC in the bone marrow. Importantly, neither of these
described progenitors has exclusive ability to produce pDC, as cDC also arise from these cells,
however they do have greater potential to become pDC40,44,45. Recently, a lymphoid-derived
pDC progenitor with exclusive pDC potential was identified as LIN- CD117int/loCD135+CD115CD127+Siglec-H+ and Ly6D+42. The initial study showed that the majority of pDC derive from
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these progenitors in vitro as well as in vivo after competitive adoptive transfer studies with CDP.
A subsequent study characterized essentially the same progenitor and suggested that pDC derive
solely from lymphoid progenitors, indicating that the pDC lineage passes through a stage that is
phenotypically similar and in a transcriptional continuum with the CD115lo CDP, but can be
differentiated with high dimensional profiling of progenitor stages43. These observations may be
consistent with the several clonal tracing studies of progenitor cells that pDC and cDC
commitment is determined at stages earlier than the phenotypically defined CDP46–48. Notably,
although the lymphoid pDC progenitor is characterized as CD115- by surface staining, it was
shown that Csf1r transcript was still present along the lymphoid developmental trajectory42,
potentially explaining a previous study that demonstrated the majority of pDC are fate mapped
for CD115/CSF1R49. Further corroboration of a lymphoid origin of pDC may be provided by the
fact that they possess rearranged IgH loci and express lymphocyte-associated genes such as
Rag1, Rag2, Ptrca, Dntt, and Ccr950,51. However, because of their dependence on transcription
factor E2-2 (discussed below) which shares many overlapping binding sites with related E2A
and HEB expressed in developing lymphocytes52, this feature is not definitive of a lymphoid
origin. In fact, it was shown that pDC derived from both myeloid and lymphoid lineages can
possess some of these lymphocyte-associated features41.

E2-2 (TCF4) is required for pDC development and maintenance of the lineage identity50. While
deficiency is lethal in humans and mice, E2-2 haploinsuffiency exists in humans and results in
Pitt Hopkins syndrome, which is mainly characterized by neurologic abnormalities and
intellectual disability but also manifests with pDC defects, indicating conserved transcriptional
requirements across species50. E2-2 is a member of the E family of class I basic helix-loop-helix
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transcription factors, along with E2-A/TCF3 and HEB/TCF12, which homo- and heterodimerize
with each other and bind to conserved E-box sequences across the genome. The activity of these
transcription factors can be opposed by ID2, inhibitor of DNA binding 2, which binds E proteins
and creates heterodimers incapable of binding DNA. CDC (particularly cDC1) express high
levels of ID2 which represses E2-2 mediated transcriptional activity; in Id2-/- mice, pDC are
greatly expanded53. PDC express an ETO family member transcriptional cofactor MTG16,
which forms a complex with E2-2 in order to inhibit ID2 and block cDC development52. PDC
also express the transcriptional repressor ZEB2 which likely targets ID2 in pDC progenitors,
allowing E2-2 to be expressed54,55. E2-2 binds to a number of pDC-associated genes and is
required for the maintenance of pDC identity after maturation. Deletion of Tcf4 in mature pDC
results in downregulation of pDC specific genes, and differentiation of pDC into cDC-like cells,
including upregulation of MHCII and an increased ability to prime T cells56,57. E proteins each
have alternative splice sites and thus exist in different isoforms; notably, the deletion of Tcf4L
(long isoform, also known as isoform B) results in a reduction in pDC development in vivo.
These mice also have an expansion of non-canonical, Id2lo CD8+ cDC1s58, which may
correspond to the CD8+ CX3CR1+ pDC-related cDC described in previous literature59,60.

E2-2 induces many other transcription factors known to be involved in the development and
function of pDC including SPIB, RUNX2, IRF8, and BCL-11A as well as functional mediators,
BDCA2, ILT7, IRF7, PACSIN1 and TLR93,50,56,61. SPIB is important for the survival of pDC
progenitors, and Spib-/- pDC have reduced IFN-I responses to TLR7 and TLR962–64. Spib-/- pDC
have increased pDC in the periphery63, suggesting a defect in bone marrow retention, while
Runx2-/- pDC fail to exit the bone marrow properly, likely due to reduced expression of the
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chemokine receptors CCR2 and CCR561.

IRF8 expression is shared by pDC and cDC

progenitors and Irf8-/- pDC have an impaired IFN-I producing capacity and enhanced ability to
induce proliferation of CD4+ T cells via MHCII presentation65. In pDC derived from the
lymphoid lineage, IRF8 expression precedes the expression of TCF4 and marks cells within a
common B cell/pDC progenitor destine to become exclusive pDC progenitors42. Thus, although
E2-2 binds the 5’ regions of IRF8 and maintains its expression in mature cells50, the
developmental relationship between E2-2 and Irf8 is unclear. BCL-11A is also expressed in both
pDC and cDC progenitors and is essential for pDC development in vivo and cDC development in
response to FLT3L but not GM-CSF in vitro.

Accordingly, BCL11A was required for

expression of FLT3 as well as IL7R in progenitor cells66. A study examining the binding sites of
BCL-11A revealed it can regulate expression of Tcf4, Mtg16, and Id2, and thus may be involved
in a feedback loop to maintain pDC identity67. Additionally, E2-2 can couple with BRD proteins
to bind a distal enhancer to increase its own expression, thus sustaining the lineage-specifying
program in developing pDC58.

FLT3 is essential for pDC and cDC development, and notably the CDP can give rise to pDC and
cDC in vitro in the absence of all other growth factors besides FLT3L68. PU.1 has long been
appreciated as an important transcription factor for development of DC and other cell lineages, at
least partly through its induction of Flt3 expression69. FLT3 signals via STAT370 and PI3Kdependent activation of mTOR71, which promotes pDC survival, as a study showing deletion of
Lamtor2, an mTOR inhibitor, in CD11c expressing cells causes expansion of pDC as mice age72.
Consistent with CDP derivation, CSF-1 may also support generation of pDC, and Csf1r-/- mice
have reduced pDC73. GM-CSF, on the other hand, is though to suppress development of pDC
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via STAT5 dependent suppression of IRF8 in pDC progenitors74,75. STAT5 can also promote
Id2 expression, which opposes Tcf4-directed pDC transcriptional programs76.
IRF777,78, along with IRF865 and IRF579, are essential for the production of IFN-I in pDC.
RUNX2 directly induces expression of IRF7 in pDC80, while MYC can suppress it thereby
limiting IFN-I production81. SPIB63 and NFATC382 synergize with IRF7 in order to aid in
transcription of IFN-I genes. PDC also have specialized epigenetic mechanisms that maintain
the hypomethylation of the IRF7 promoter, a process that involves a pDC-enriched epigenetic
regulator, CXXC5, and Tet2 DNA demethylase83.
The developmental trajectory of pDC and the transcriptional mechanisms that facilitate lineage
commitment are an essential part of pDC biology that would shed light onto the complex
phenotype and functional roles that pDC exhibit in maturity. After defining these pathways in
homeostasis, it will also be essential to understand how development of pDC and lineage
commitment is impacted by pathologic conditions, as pDC are implicated in a vast collection of
diseases. Understanding pDC development will undoubtedly elucidate mechanisms underlying
the heterogeneity within pDC and the increased recognition that pDC, as we classify them today,
may actually comprise multiple populations of cells that have different functions.

This

heterogeneity of pDC will be discussed in a later section (1.7).

1.4 pDC are early and robust producers of type I interferons during
viral infections.
As noted in the previous section, plasmacytoid dendritic cells (pDC) possess a multitude of
features that distinguish them from conventional dendritic cells (cDC). Perhaps most strikingly,
these cells produce extremely high levels of IFN-I1,2 in response to ligation of endosomal TLR7
by single stranded (ss) RNA or TLR9 by double stranded (ds) DNA rich in unmethylated CpG
10

sequences84. These ligands reach the endosomal compartments of pDC by several mechanisms.
Some ssRNA viruses such as vesiculostomatitis virus (VSV) and Sendai virus (SeV) can infect
pDC and generate replicative intermediates. These products are removed from the cytosol after
being encircled in membrane and directed to fuse with TLR7+ endosomes in a process known as
autophagy85. Additionally, large DNA immune complexes are recognized by a non-canonical
autophagic process, in which they are phagocytosed by pDC and recognized by TLR9 via
microtubule-associated protein 1A/1B-light chain 3 (LC3)-associated phagocytosis (LAP)86.
Other viruses, such as herpes simplex virus (HSV), influenza virus, HIV, and coxsackivirus B
(CVB), can be engulfed by pDC via receptor mediated endocytosis and delivered to TLR7/9+
endosomes, a mechanism that does not require direct infection of pDC87–90. In general, pDC are
quite resistant to viral infection, and several studies have shown that when infection does occur,
viral replication only occurs in a subset of pDC, with the uninfected cells taking over the role of
interferon producers. This mechanism is supported by a newer paradigm in which pDC respond
to infected cells rather than free virus. Studies have shown that in multiple RNA viral infection
models, including hepatitis C, LCMV, Dengue and West Nile virus, infected cells transfer viral
RNA containing exosomes or immature viral particles through a contact-dependent
mechanism91–94.

Upon ligation of nucleic acid ligands, TLR7 and TLR9 signal via MyD88, which binds IRF7 to
form a signaling complex with IRAK4 and TRAF695,96. IRF7 is then phosphorylated which
allows translocation into the nucleus and induction of interferon-stimulated genes (ISGs)77. A
high basal level of IRF7 has been hypothesized to explain the rapid and unique production of
IFN-I upon administration of TLR7 and TLR9 ligands97. Interestingly, pDC appear to be able to
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respond to some viruses such as VSV and MCMV without the IFNAR-mediated feedback loop
that is essential for production of IFN-I by other cell types97,98. This may not be a universal
phenomenon as IFNAR-/- pDC do not produce optimal IFN-I in response to synthetic TLR9
ligands98. PDC also can be activated via CD40, which signals through the alternative nuclear
factor-kB (NF-κB) pathway. CD40 is a weaker inducer of IFN-I than TLR7 or 9 ligation but can
induce expression of costimulatory molecules and increase antigen presentation by pDC14.

In addition to IRF7, MyD88 recruits IRF5, which cooperates with the NF-κB pathway
downstream of TRAF6 and induces production of proinflammatory cytokines and chemokines in
pDC99. Additionally, signaling pathways downstream of TLR7/9 will induce pDC maturation,
leading to increased expression of MHCII and costimulatory molecules CD80, CD86, and CD40.
Temporal regulation of vesicular trafficking may account for these disparate responses to the
same stimuli, as TLR9 ligation in early endosomes leads to IFN-I production, while ligation in
late endosomes tends to promote maturation and antigen presentation. The endosomal stage in
which activation of TLR9 occurs may depend on the structure of the higher order structure of
nucleotide, the properties and evolutionary strategies of the particular virus, or the mechanism by
which pDC encounter viral particles, i.e. via endocytosis or autophagy100.

1.5 The strategies used to assess pDC function have limitations.
In subsequent sections we will review the function of pDC within the immune system. Because
many studies have demonstrated the function of pDC in vitro or through depleting antibodies
(anti-Bst1, anti-Ly6C/G) that cross react with other cell types, it is important to reevaluate these
findings utilizing mice that can be specifically depleted of pDC. Ly6C is expressed by pDC,
plasma cells, NK cells, inflammatory monocytes, CD8+ memory T cells, and granulocytes101–103,
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while BST-2, is expressed by many cells upon exposure to IFN-α or IFN-γ104.

Genetic

approaches have lead to more faithful and specific deletion of pDC, allowing for assessment of
function in various diseases (Table 1.1).

In addition to clarifying the role of E2-2 in pDC development and maintenance, the Itgax-Cre
Tcf4F/F mouse has depletion of pDC. These mice have a 50% reduction of pDC in the bone
marrow, but a 90% reduction in the spleen56,57. Additionally, they have an expansion of cDClike cells that results from loss of the pDC lineage-defining transcriptional program that is driven
by E2-256, which may cofound functional studies. Additionally, monoallelic deletion of Tcf4 has
been used as a model of pDC depletion105, as these mice have a 50% reduction of pDC in the
spleen and bone marrow, as well as an impairment in IFN-I production50. E2-2 is expressed by
many other cells in the body, so defects in these mice cannot be conclusively attributed to pDC.

Other genetic models utilize expression of a pDC-specific gene to drive deletion. Our lab has
generated transgenic mice that express the diphtheria toxin receptor under the promoter of
CLEC4C (BDCA2), a protein expressed specifically by human pDC106. We hypothesized that
there would be conserved sequences in the promoter region of CLEC4C that bound transcription
factors involved in development of both human and mouse pDC. This hypothesis turned out to
be correct, as it was later shown that E2-2 interacts with elements of the CLEC4C promoter in a
human pDC cell line56. In result, we generated a mouse that exclusively expresses diphtheria
toxin receptor on pDC and thus can be specifically and transiently depleted of pDC by
intraperitoneal administration of diphtheria toxin (DT)106. We have established that through
repeated administration of DT, pDC can be depleted for extended periods of time106,107, however
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it has been shown that complete depletion is likely only feasible for up to 9-10 days, as long term
administration results in loss of DTR expression in pDC108. Another DTR mouse was generated
to target pDC, with DTR driven by the promoter of Siglec-H109. These mice are sufficiently
depleted of pDC but also lack macrophage populations, which can lead to an overestimation of
the immunologic functions of pDC12. Importantly, Siglec-H is expressed by microglia, so these
cells may be affected as well.

1.6 pDC enhance the innate anti-viral immune response and shape
adaptive immunity.
Because of their efficient and robust production of IFN-I, studies involving pDC have focused on
their function in antiviral immunity, but a definitive and non-redundant role for pDC during viral
infection has been difficult to establish. While pDC do contribute a large proportion of the initial
wave of type I IFN and promote early viral containment in a variety of infections such as
MCMV, VSV, and acute LCMV29,106,110,111, their importance to limiting viral replication
becomes less important as the infection progresses and other cells take over as major interferon
producers. In fact, in the majority of viral models investigated, the absence of pDC-derived IFNI does not have an impact on overall morbidity or mortality of the host, with the exceptions being
mouse hepatitis virus and systemic HSV29,112–114. It appears that due to their rapid production of
IFN-I, pDC are particularly important when encountering a virus that can proliferate quickly or
immediately access the circulatory system. In the more typical route of infection, via mucosal
surface, pDC may be less important as stromal cells and immune cells resident to these barrier
sites are able to produce IFN-I to limit viral replication. Additionally, pDC derived IFN-I and
IL-12 may be important for activating NK cells to some viruses such as HSV1 and HSV2,
however, when NK cells can recognize virus directly, as in the case of MCMV, pDC-depletion
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does not deter NK activation29,106. Thus, although pDC are largely classified as part of the innate
antiviral immune system, it is important to examine roles of pDC outside of their early, robust
production of IFN-I after encounter with virus.

Along with their role in directly limiting infectivity of virus via production of type I IFN and
induction of an antiviral state in hematopoietic and stromal cells, pDC can influence the adaptive
response to viral infection. This was first shown in VSV infection, where pDC promoted the
cytotoxic T cell response by enhancing antigen-specific CD8 T cell survival, likely through
production of IFN-I or by limiting activation induced apoptosis through early viral control106.
Additionally, in chronic LCMV Docile, pDC help to promote CD4+ T cell responses, which
provide help to CD8+ cells essential for viral clearance. This is also likely through IFN-I
secretion, as CD4+ T cell survival during chronic LCMV infection is highly dependent on
IFNAR signaling, although it is possible that other pDC derived cytokines play a role112.
In systemic HSV-1, pDC also promote IFN-γ producing viral-specific T cells29.

Of note, in VSV and LCMV antigen presentation was excluded as potential mechanism by which
pDC influence T cells. However, this aspect of pDC biology is difficult to characterize, as pDC
do not perform well many in vitro assays in which pDC are incubated with antigen and exposed
to antigen-specific cells5. It is clear that pDC are capable of activating T cells when presented
with soluble proteins such as ovalbumin or hen egg lysozyme either in vitro or in vivo115–117.
PDC can also efficiently present exogenous antigen coupled to antibodies targeting particular
cell surface receptors expressed by pDC such as BST-2, DCIR, BDCA2, and Siglec-H116,118–120.
Similarly, it appears that pDC can be very important for sustaining T cell activation at sites of

15

infection or after cells that first been primed by cDC121,122. In contrast to cDC, pDC can
continually present antigen via MHCII after becoming activated. They utilize the p1 promoter of
CIITA, instead of the pIII promoter used by cDC, and this promoter is not silenced after pDC
become activated123. Unlike cDC which downregulate antigen processing, but maintain high
levels of peptide:MHCII on their surface after activation, use of the p1 promoter provides pDC
the ability to continually present antigen even after being infected by virus or stimulated via
TLR7/9 by viral material. Additionally, MHCII turnover is not downregulated in activated pDC,
as it is in activated cDC117. This property of pDC also likely makes them less efficient antigen
presenters when compared to cDC, as they are unable to hold a large number of peptide:MHCII
complexes on their surface for an extended period of time, thereby increasing the likelihood of
encountering cognate T cells. A recent study has reveal a new potential role for pDC in CD8+ T
cell priming during administration of the attenuated vaccinia virus vaccine. Here, pDC serve as
a facilitator between XCR1+ cross presenting DC and CD8+ T cells. CD8+ T cells recruit both
pDC and XCR1+ through secretion of CCR5 ligands and XCL1, respectively, and pDC secrete
local IFN-I to facility XCR1+ DC maturation and cross presentation124.
PDC can also play a role in chronic infection. In chronic and acute strains of LCMV, they
appear to become exhausted, marked by reduced IFN-I and TNF-a production, through a
mechanism that involves IFN-I mediated suppression of pDC output from the bone marrow and
TLR7 mediated suppression of E2-2 in peripheral cells125. Notably, negative feedback from
IFN-I is also present in acute infection, causing apoptosis of pDC via IFNAR signaling126. PDC
function in HIV infection has been of interest for a long time, given the recognition that in
addition to CD4+ T cells, pDC are lost over the course of disease. In HIV, pDC can produce
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robust IFN-I that is protective at the onset of infection but drives immunopathology later in the
disease127,128.

1.7 Heterogeneity exists within the classically defined pDC
population.
Many studies have suggested phenotypic heterogeneity within pDC, often ascribing different
functional capacities to subsets within the pDC population. This idea has received new interest
as of late as high dimensional single-cell analysis of human dendritic cells has revealed a
previously unappreciated subset of DC that has similarities to both cDC and pDC46,129,130.
Importantly, part of this population expresses cell surface markers that are used to define the
pDC population, and therefor fall within the classical pDC gate in flow cytometry.

This

population is marked by AXL and SIGLEC6 (and therefore named AS DCs)129. It encompasses
cells with a spectrum of gene expression, containing CD123+CD11clo/- cells enriched for a pDC
gene signature and CD123loCD11c+ cells enriched for a cDC gene signature. Comparing the
AXL+ SIGLEC6+ cells with pure pDC (pDC that exclude the AS DC subset), revealed that only
pure pDC were capable of IFN-I production46,129,130, while cDC-like AS DC were the only subset
that produced IL-12p70, and pDC-like AS DC were the only subset to produce IL-8129. AS DC
were also better at stimulating proliferation of allogeneic CD4+ and CD8+ T cells, compared to
pure pDC129,130. These cells were also present in the T cell zones of human tonsils, blood, and
spleen, but absent from skin, which mirrors pDC tissue distribution130.

Amongst the three studies that have described these cells, a common phenotype has emerged for
the pDC-like AS DC: AXL+ SIGLEC6+ CX3CR1+ CD2+ CD5+ CD33+ SIGLEC1+.

They

express HLA-DR and have intermediate to high expression of CD123 and BDCA2 (CLEC4C),
while pure pDC tend to have uniformly high expression for those markers. These cells also seem
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to express lower levels of E2-2 compared to pure pDC, consistent with the absence of traditional
pDC features such as IFN-I production46,130. Moreover, previous studies have identified
CD2+CD5+ pDC in humans that have overlapping functions with the pDC-like AS DC8,131.

Using transcript data from scRNAseq, trajectory mapping indicated that AS DC form a
continuum between pDC and CD1C+ DC129. Additionally, high dimensional protein expression
data collected by CyTOF showed that these cells localize near pDC and cDC2 on viSNE maps
and cluster closely with both pDC and cDC2 unsupervised hierarchical clustering130.

The

original paper that identified the pDC-like AS DC subset suggested that it represents an early
pre-DC subset, capable of differentiation to cDC1 and cDC2 after in vitro culture46. However,
Villani et al. found they preferentially differentiate into CD1C+ cDC2, with little differentiation
potential to CLEC9A+ cDC1. Corroborating their conclusions, AS DC are not proliferative cells
and function as mature DC ex vivo without need for in vitro differentiation129.

Thus, it is

possible that AS DC represent a precursor of cDC2 or an intermediate state that indicates some
transition between pDC and cDC2 these cells after exiting the bone marrow.

The phenotype of the human AS DC cells match pDC-like cells that have been described in the
mouse as well as previous reports of pDC diversity in humans8,131. Most notably, these cells
mirror a distinct subset of CX3CR1+ CD8α+ DC in the mouse that lacks IFN-I and IL12p70
production, is capable of stimulating proliferation CD4+ T cells, and has a gene expression
profile similar to both cDC2 and pDC59,60.

CX3CR1+ CD8α+ DC harbor D-J IgH gene

rearrangements and are dependent on Tcf4 for development, indicating they may share a
developmental pathway with pDC. Cells similar in phenotype arise in CD11c-Cre Tcf4F/F and
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Tcf4L deficient mice, indicating they may originate from pDC precursors that do not have
adequate E2-2 activity56,58.

Interestingly, Rodriguez et al. also identified a CX3CR1+ pDC-like cell that has a developmental
relationship with classical pDC. They used scRNAseq to profile in vitro IL7R+ lymphoid
precursor-derived pDC or CDP-derived pDC and compared them to a large number of mature
pDC isolated from the spleen and bone marrow that they characterized by scRNA sequencing.
They were able to identify a small cluster of mature pDC in vivo (~5% of total) that resembled
the in vitro CDP-derived pDC, suggesting a myeloid ontogeny of these cells. They went on to
show that these cells could be identified using the Zbtb46gfp/+ mouse as Zbtb46+BST2+SiglecHint, and strikingly, they exclusively expressed CX3CR1 compared to other pDC clusters.
Unlike previous reports, these cells were capable of producing IFN-I to CpG-A. However, they
did not produce IFN-I with CpG-B stimulation, suggesting some functional specification from
classical pDC. Resembling the human pDC-like cells and the CX3CR1+ CD8α+ mouse DC,
these lymphoid derived pDC could stimulate proliferation of CD4+ T cells. Markedly, this study
showed that these cells take up OVA protein in vitro and induce proliferation of OT-II cells,
suggesting ability to actually process and present peptide that was not previously demonstrated
by assays with allogeneic T cells. Thus, these studies suggest that the heterogeneity within the
pDC population may be explained by ontogeny of pDC, with the pDC-like/AS DC described in
the mouse and human derived from the CDP and traditional pDC derived from the CLP. This
observation will need to be investigated further, and already, a conflicting deposited study
suggests that Axl+ Siglec6+ pDC-like cells exist in the mouse and are derived from the CLP, as
indicated by labeling in a CD79A (Mbl) fate mapped Mbl-Cre Rosa26-YFP mouse132.
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Additionally, since the precursors to the lymphoid progenitor-derived pre-pDC are unknown, it is
possible that pDC develop in sequential stages with myeloid features and lymphoid features, and
these subsets of pDC emerge as mature cells during different stages of development. This
developmental model is supported studies that show that pDC may share a common precursor
with specific cDC lineages. In fact, it was recently shown that cDC1 have a precursor that likely
requires expression of E proteins and low levels of ID2 to maintain IRF8 levels, prior to shifting
to a state in which BATF3 can maintain IRF8. This suggests the possibility that an E2-2+
progenitor exists that may give rise to pDC and cDC1.

The functional division of labor between different types of pDC is supported by previous studies.
For example, several studies using IFN-I reporter mice show that only a fraction of pDC produce
IFN-I to any given stimulus98,133,134. Additionally, a recent study has shown that human pDC
diversify into three stable populations after stimulation with cytokine or microbial products135.
Two of these subsets show preferential IFN-I production or antigen presentation ability, while
one retained both functions.

Of note, this study ruled out contamination with AXL+ DC,

suggesting, along with Alcantara-Hernandez et al., that ‘pure pDC’ do possess some ability to
trigger adaptive T cell response130,135. Characterizing the true functional and developmental
diversity within pDC and understanding the relationship between these properties should be
prioritized in future studies.

1.8 pDC are pathogenic in several autoimmune diseases.
Aberrant pDC function has been implicated in an alarming number of autoimmune or
inflammatory diseases, including SLE, Sjogren’s syndrome, systemic sclerosis (scleroderma),
psoriasis, type I diabetes, atherosclerosis, and alopecia areata3,6,136. Given the common presence
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of an ISG (interferon stimulated gene) signature in patients with autoimmune diseases, the role
of pDC as the professional IFN-I producing cells is a logical area of interest. Here we will
review the role of pDC in SLE, psoriasis, and Type I diabetes, as these pathologies have more
evidence than others.

However, a more ubiquitous role for PDC in autoimmune and

inflammatory diseases should not be ruled out.

Lupus is a disease characterized by autoantibodies that form immune complexes with
endogenous nucleic acids and other nuclear antigens. Many lupus patients have an interferon
signature that correlates closely with clinical disease, and in mouse models of lupus, IFNAR
deficiency ameriolates the disease. PDC are reduced in the blood of SLE patients due to
increased trafficking to the tissues, particularly to sites of active disease. Furthermore, pDC are
stimulated to produce IFN-I in response to nucleic acid-containing immune complexes, perhaps
through CD32 mediated endocytosis and delivery to TLR7/9+ endosomes136–138. While the
pathogenic role of TLR7 in lupus is clear, TLR9 deficient mice are actually protected from
lupus139, suggesting that the mechanism by which immune complexes activate pDC may be more
complex than our current understanding. Additional pDC activation stems from neutrophils that
release extracellular traps (NETs) containing DNA and the anti-microbial peptide LL-37, which
are thought to trigger the TLR9 pathway140. Interestingly, studies have shown that pDC from
females produce higher levels of IFN-I, partially due to estrogen and partially due to cell intrinsic
mechanism141,142.

This correlates well with the predominance of SLE in female patients.

Additionally, in SLE patients, TLR7 and TLR9 trigger the NF-κB pathway, which promotes
pDC survival and results in resistance to death by glucocorticoid therapy143. Likewise, studies
have shown that pDC have a longer life span in mice with lupus-prone genetic backgrounds144.
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Notably, high doses of corticosteroids are required in SLE patients and monotherapy is often
insuffiecient to control disease. Also, oral glucocorticoids do not tend to decrease the ISG
signature found in SLE patients138,143.

Importantly, transient deletion of pDC using the CLEC4C-DTR mice ameliorated disease
features in a genetic mouse model (BXSB) of lupus107. Moreover, this was confirmed with in
two models of lupus-prone mice with Tcf4 haploinsufficiency, which results in partial pDC
reduction105. These studies revealed that pDC are largely responsible for the IFN-I response to
immune complexes but also for the production of autoantibodies themselves. Previous studies
suggest that human pDC can induce plasma cell differentiation via IFN-I and IL-6 in vitro145,
however how pDC impact the autoantibody response in vivo is still unclear. Rowland et al.
demonstrated pDC depletion also results in impaired T cell activation and expansion, suggesting
that T cell activation by pDC could also promote autoantibody production.

PDC are expanded at the time of diagnosis in T1D patients146, and in non-obese diabetic (NOD)
mice, pDC can be found infiltrating pancreatic islets147. B-1a cells and neutrophils are also
recruited to the islets where B-1a cells secrete autoreactive IgG, causing neutrophils to release
LL37 which binds self DNA. Autoantibodies complexed with self DNA and LL37 activate pDC
via the MyD88-TLR9 pathway leading to IFN-I production in the islets147. Depletion of pDC
using anti-BST2 antibody or genetic deletion of pDC with Cd11c-Cre Tcf4F/F mice resulted
reduced development of T1D in NOD mice147,148.

In pDC-deficient NOD mice, fewer

autoreactive CD8+ T cells and lower levels of IFN-g were detected in the islets.
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In psoriasis, pDC likely play a role in inflammation through recognition of endogenous nucleic
acids. PDC infiltrate the psoriatic lesions and produce IFN-I149. LL37 is also prominently
expressed in psoriatic skin and drives IFN-I production150,151. Again, as in SLE and T1D, in
psoriasis, it is proposed that pDC recognize self-DNA and RNA in complex with LL37, which
triggers IFN-I via TLR9 or TLR7 respectively. LL37 stabilizes endogenous DNA and RNA
extracellularly and prevent degradation. In vitro experiments show that LL37 complexes with
self-DNA and transforms it from a generally inert stimulus for pDC into aggregated and
condensed structures that can be internalized within pDC. Furthermore it facilitates the entry
and retention of self-DNA into early endosomes containing TLR9150, though mechanisms that
are unclear. Crossing the CLEC4C-DTR mice to a genetic model of psoriasis in which Jun and
JunB are deleted in the epidermis by a tamoxifen driven Cre revealed that depletion of pDC prior
to disease onset resulted in milder disease152. Another study using imiquimod, a TLR7 agonist,
to induce psoriatic-like skin lesions, showed that pDC-depletion had no effect153. Thus, although
there is evidence that pDC are activated by a major driver of psoriatic disease, LL37, it remains
unclear if they are pathogenic in psoriasis. Whether the mouse models of psoriasis in which
pDC-depletion has been studied faithfully reflect the induction of this autoimmune disease or
just mirror its eventual manifestations is unclear.

1.9 pDC induce tolerance in a multitude of settings.
Like cDC, when activated through TLRs or other pattern recognition receptors, pDC are able to
promote inflammation by stimulating T cells through antigen presentation on MHC molecules
and upregulation of costimulatory molecules like CD80, CD86, and CD40. However, in settings
where pDC do not receive these conventional activation signals, including in settings of tumors,
transplant of alloantigen, and exposure to innocuous antigen, pDC-T cell interactions have been
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shown to result in tolerance115,154,155. This dual function of pDC is very similar to observations
made in the field of conventional dendritic cells, in which immature or unstimulated cDC
promote tolerance while mature cDC induce inflammation.

However, unlike cDC which

continually traffic from tissue to lymph node, promoting tolerance in the absence of
inflammation156, the environmental signals that stimulate a tolerogenic program in pDC are still
unclear. It seems that pDC are able to contribute to central tolerance in the steady state, as
reports have shown that CCR9+ pDC traffic to the thymus and promote deletion of self-reactive
thymocytes157. CCR9+ pDC are also able to promote T regulatory cell function in vitro and
suppress graft versus host disease induced by transfer of allogeneic CD4+ T cells into irradiated
hosts158. Additionally, pDC exposed to the tumor microenvironment promote IL-10 producing T
regulatory cells which oppose anti-tumor immune responses159. Reports have suggested that
pDC in tumor draining lymph nodes express indoleamine 2,3-dioxygenase (IDO)154, which can
directly inhibit effector T cells through depletion of tryptophan as well as promote the generation
of T regulatory cells through production of kynurenine which engages the aryl hydrocarbon
receptor in both T cells and antigen presenting cells (APC)160. Generation of T regulatory cells
in the periphery has also been reported to be mediated by production of TGF-β by pDC, which
required interactions with iNKT cells through PD-L1161.

However, in an in vitro system,

differentiation of naïve T cells to T regulatory cells was found to be facilitated through pDC
expression of ICOS-L162. Furthermore, human pDC can inhibit T cell proliferation in vitro
through production of granzyme B, in a mechanism that is perforin independent163. Thus, the
reported mechanisms by which pDC induce tolerance are vast and seem to depend on the
experimental model being investigated.
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1.10 Gut associated pDC have unique features.
Compared to other anatomical locations, pDC are relatively abundant in the gut, where they
comprise about 1% of the intraepithelial immune cell population of the small intestine164.
Furthermore, pDC in the gut seem to possess distinct properties from those residing in the
periphery; pDC in the Peyer’s patches do not secrete IFN-α in response to TLR9 agonist CpG
DNA165 and may promote Th17 responses166, although this was demonstrated only in vitro. In
addition, virtually all pDC in the gut express CCR9+, and CCR9-/- have a complete lack of pDC
in the gut. Given the role of CCR9+ pDC in generating tolerance in the periphery as discussed
above, gut associated pDC may also demonstrate tolerogenic properties. In fact, pDC are
reported to be essential for oral tolerance to haptenated endogenous proteins and dietary protein.
In this study, the authors demonstrated that hapten feeding abrogated the development of a
delayed type hypersensitivity (DTH) reaction to hapten in the skin. Oral tolerance was absent
when pDC were depleted with 120G8, and the authors went on to demonstrate that pDC residing
in the liver and mesenteric lymph node (MLN) mediated deletion or anergy of hapten specific
CD8+ T cells. The authors also demonstrated a role for pDC in the induction of oral tolerance to
OVA, but did not investigate the impact of pDC on antigen specific CD4+ T cells which are
thought to drive DTH to OVA protein167.

1.11 pDC inhibit Th2 driven immune responses.
As discussed above, pDC drive tolerance in many settings. It has also been appreciated that pDC
can drive tolerance to innocuous antigen and prevent pathology driven by Th2 effector cells in
mouse models of asthma. The initial study describing this phenomenon demonstrated that
depletion of pDC through 120G8 antibody resulted in sensitization and development of asthma
pathology upon inhalational exposure to OVA in the absence of adjuvant, a treatment that
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typically results in tolerance115. The mechanism by which pDC inhibit effector responses in
asthma was unclear in this study; however, subsequent studies have suggested that expression of
PD-L1168 or retinaldehyde dehydrogenase169 by pDC induce T regulatory cell generation. Like
the many other studies demonstrating tolerogenic roles for pDC, these studies are confounded by
the nonspecific depletion methods used as well as sensitization protocols that involve
intraperitoneal injection of OVA as a model allergen rather than exposure via the more
physiological mucosal route.

Therefore, additional studies are needed to provide a clear

understanding of pDC involvement in Th2 immune responses. Such investigation may provide
potential therapeutic options for the large portion of the population that is impacted by allergic
and atopic diseases as well as extend knowledge of the immunological mechanisms that drive
Th2 cell priming.

It has long been recognized that respiratory viral infections in childhood are a major risk factor
for subsequent development of asthma later in life. In fact, respiratory syncytial virus (RSV)
infection, a major cause of morbidity and mortality in young children across the globe, is an
independent risk factor for asthma, and a recent study examining two large cohorts demonstrated
that 13% of asthma cases were preceded by RSV infection170. In the clinical literature, pDC
have been associated with this post-viral asthma phenomenon. In a prospective study, peripheral
blood pDC in infancy were found to be inversely correlated with lower respiratory tract
infections and the diagnosis of asthma by 6 years of life171. Similarly, polymorphisms in TLR7
are associated with asthma172, and asthma patients have been found to have hyporesponsive
TLR7 responses173.
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Furthermore, there is some evidence in mice that pDC regulate virus-induced immunopathology
of the lung. Human RSV infected mice depleted of pDC with 120G8 antibody develop enhanced
airway hyperresponsiveness and elevated levels of IL-4, IL-5, IL-13 and IFN-γ in the mediastinal
lymph nodes. While optimal control of the virus was dependent on pDC production of IFN-I,
development of airway hyperresponsiveness and immunopathology was not impacted by IFN-I.
This provides evidence that the severity of the viral infection does not necessarily correlate with
post viral immunopathology, but rather cells of the immune system can modulate the progression
of acute viral infection to chronic asthma. In support of this, another study using the CLEC4CDTR mice showed that depletion of pDC in neonatal mice (1 week) along with infection of
pneumovirus resulted in marked bronchiolitis and development of airway hypersensitivity and
asthma-like features upon reinfection later in life. This protection was also not dependent on
IFNAR signaling, but resulted from an expansion of Neuropilin+ T regulatory cells mediated by
pDC expression of semaphoring 4a (Sema4a)175. Adding to the complexity, another study
demonstrated that in a mouse model of influenza virus, ablation of IFN-I signaling resulted in
elevated immunopathology as well as an increase in ILC2 within the lung176. Thus, there may be
interferon-dependent and independent mechanisms by which pDC can regulate post-viral
asthma. Given the link between viral infection and subsequent type 2 immunopathology and the
fact that pDC have reported roles in facilitating anti-viral responses as well as in promoting
tolerance, the evaluation of pDC in models of type 2 immunity is warranted in future studies.
The presence of pDC in asthmatic sputum and atopic skin lesions, and the presence of FcεRα on
human pDC10 heightens the suspicion that pDC could be involved in type 2 immunity-driven
pathologies across species10,27.
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1.12 Conclusions
This thesis chapter has served as an overview of pDC biology in order to provide context for the
study described in Chapter 2. We became interested in studying the relationship between pDC
and type 2 immunity after we unexpectedly found that our CLEC4C-DTR/+ pDC-depleted mice
developed atopic dermatitis-like skin lesions after exposure to ink from a permanent marker. In
order to explore how pDC inhibit allergic pathology to innocuous antigen, we decided to utilize a
model of Th2 driven cutaneous contact hypersensitivity (CHS) induced by FITC hapten. This
model has clear priming and effector phases, facilitating the evaluation of pDC function in each
phase. Furthermore, there are CHS models driven by Th1 and Th17 effector cells which allowed
us to assess if pDC act to inhibit Th2 pathology uniquely, or are capable of universally inhibiting
contact hypersensitivity reactions through induction of T regulatory cells or anergic T cells.

In the FITC CHS model, FITC is applied epicutaneously in a solvent containing dibutyl
phthalate, a chemical known to induce TSLP production from keratinocytes and drive contact
hypersensitivity reactions in humans.

TSLP stimulates cutaneous cDC to up regulate

costimulatory molecules and migrate to the draining lymph node (DLN), where they prime naïve
CD4+ T cells to differentiate into Th2 cells177. Indeed, FITC CHS is known to be dependent on
IL-4 and STAT6178. This process also induces elevation of serum IgE, some of which is reactive
against the FITC hapten itself179.

In the absence of TSLPR, the response is much less robust,

with fewer FITC+ migratory cells in the DLN and less production of IL-4 and IL-5 by cells in the
DLN177. The subset of cDC that responds to TSLP is controversial177,180,181, and further
characterization of the DC subset(s) responsible for generation of FITC induced CHS is required.
During the elicitation phase in which FITC is topically applied to a different anatomical location,
there is an antigen non-specific inflammation phase in which haptens stimulate keratinocytes and
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mast cells in a manner similar to the sensitization phase. This process activates the vascular
endothelium to express adhesion molecules, which allow granulocytes and hapten-specific T
cells to infiltrate the skin.

Antigen experienced T cells infiltrating the skin are activated by

cutaneous DC and produce cytokines such as IL-5 which further attracts inflammatory cells to
the skin and amplifies the response182,183. In Chapters 2 and 3, we will describe our findings
regarding the role of pDC in this model and contextualize them within the broader literature
overviewed here.
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Genetic
Strain
Tcf4f/f Itgax-Cre

Effect
Constitutive lack of
peripheral pDC

Tcf4+/-

50% reduction in pDC

CLEC4C-DTR/+
(Transgenic; aka
BDCA2-DTR/+)

Robust, transient
depletion (48h) of
mature pDC

SiglechDTR/+
(HBEGF knocked
into Siglech locus)

Robust, transient
deletion (48h) of pDC

Antibody-mediated
Ab
Anti-BST2
(clone 120G8,
mPDCA-1)

Anti-SiglecH (clone
440c)
Anti-Ly6C/G
(clone Gr-1)

Effect
pDC depletion

Inhibition of IFN-I
secretion in pDC
pDC depletion

Caveats
Incomplete deletion on
B6 background, 50%
depletion of bone
marrow pDC, low
efficiency of Itgax-Cre
in pDC, expansion of
cDC-like cells
Partial reduction of
pDC, haploinsufficiency
possible in other cells
Transient, depletion
only efficient for 9-10
days

Reference
Cisse et al., 2008
Cervantes-Barragan
et al., 2012

Transient, monoallelic
Siglech deletion,
depletion of
macrophages reported

Takagi et al., 2011

Cisse et al., 2008
Sisirak et al., 2014
Swiecki et al., 2010

Caveats
Not useful during
inflammation/infection
models, as Bst-2 expression
is induced by IFN-I and
IFN-II, may deplete some
plasma cells at steady state
Nonspecific effects likely
Non-specific, depletes
granulocytes, NK cells, etc.

Reference
Asselin-Paturel
et al., 2003
Krug et al.,
2004
Blasius et al.,
2006
Blasius et al.,
2004
Nakano et al.,
2001

Table 1.1 Methods of pDC Depletion and Functional Modulation Experimental strategies
used in the literature to investigate the function of pDC by depletion or by targeted functional
modulation.
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2.1 Abstract
Plasmacytoid DCs (pDCs) are a major source of type I IFN (IFN-I) in immune responses. They
also contribute to naïve CD4+T cell differentiation and have been reported to prime Th1, Th2 or
tolerogenic T cells depending on cell surface and soluble signals that they provide to CD4+T
cells together with MHC-peptide complex.

Here, we demonstrate that pDC depletion

exacerbates a model of skin contact hypersensitivity (CHS) by skewing CD4+T cells towards
Th2 and limiting Th1 differentiation. Remakably, this bias was independent of IFN-I and
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antigen presentation. In fact, pDC depletion altered DC representation in the skin draining
lymph nodes during the sensitization phase of CHS; there were fewer Th1-priming CD103+cDC1
and more Th2-Th17-priming CD11b+cDC2. Depletion of pDCs also induced expansion of noncanonical cDCs that closely resemble pDCs but appear poised to prime Th2. This subset
expressed CX3CR1+ and resembled previously pDC-related cells that are specialized in antigen
presentation.

These results support a model in which pDCs impact CD4+T cell priming

indirectly by influencing the DC2:DC1 ratio in the lymph node niche where DCs prime T cells.

2.2 Introduction
Plasmacytoid dendritic cells (pDCs) are a subset of bone marrow (BM)-derived DCs that
produce substantial amounts of type I interferons (IFN-I; i.e. IFN-a, IFN-b) upon recognition of
viral and microbial nucleic acids through toll-like receptor (TLR) 7 and TLR91, 2, 3, 4. Secreted
IFN-I binds to the IFN-I receptor (IFNAR) on pDCs, completing an autocrine loop that sustains
IFN-I production5. pDC secretion of IFN-I is mostly evident at early timepoints during viral
infections and mediates immediate containment of viral replication but becomes less important
later on during infection as other host cells become more dominant producers of IFN-I.

In addition to a robust IFN-I response against viral infection, pDCs have been shown to influence
adaptive immune responses. Since pDCs express MHC class II molecules as well as the
costimulatory molecules CD40, CD80 and CD86, they can present antigens to CD4+ T cells,
although not as efficiently as conventional DCs (cDC)6. However, studies focusing on the impact
of pDCs on CD4+ T cell responses have yielded widely varying results. Initial studies reported
that pDCs induce Th2 polarization of CD4+ T cells7. A subsequent study showed that pDCs
induce Th1 polarization through secretion of IFN-I and, in part, IL-128. It was then proposed that
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pDCs may be flexible in directing Th1 and Th2 development, depending on antigen dose and
TLR stimulation9. PDCs were also shown to promote T cell tolerance to tumor antigens10, 11, 12,
alloantigens13, as well as innocuous inhaled antigens14 and oral antigens15. The paradigm
commonly used to interpret these differences is that the ability of pDCs to differentially prime
Th1, Th2, Tregs or induce T cell anergy or deletion depends on the cell surface and soluble
signals they provide to CD4+ T cells in addition to the MHC-peptide complex. PDCs activated
through TLRs express costimulatory molecules and secrete cytokines, such as IFN-I and IL-12,
which induce Th1 responses8. In contrast, pDCs promote Th2 when induced to express OX40L16.
PDCs support tolerogenic T cells (Tregs, Tr1) or T cell anergy/deletion when they are not
appropriately stimulated or are induced to express indoleamine, 2,3-dioxygenase (IDO)17, 18, 19,
ICOSL20, programmed death-ligand 1 (PD-L1)21, 22 or granzyme B23. Additional studies have
proposed that pDCs can also contribute to immune tolerance by capturing antigens in peripheral
tissues and migrating to the thymus, where they induce deletion of antigen-specific thymocytes24.

In many of these studies, the impact of pDCs on CD4+ T cell responses has been addressed by
depleting pDCs with various antibodies. However, additional cell types are often also depleted
due to the semi-promiscuous expression of the antigens recognized. To avoid this caveat we have
generated a transgenic mouse that selectively expresses the diphtheria toxin receptor (DTR)
under the control of the promoter of the human CLEC4C gene, which encodes the pDC-specific
C-type lectin CLEC4C (also known as BDCA2). Thus, injection of DT in these mice selectively
depletes pDCs25. In this study we found that depletion of pDCs in CLEC4C-DTR Tg mice
markedly augmented skin inflammation in a model of contact hypersensitivity (CHS) induced by
the hapten FITC. Depletion of pDCs enhanced Th2 responses, demonstrating that pDCs
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negatively regulate Th2 responses. Unexpectedly, the regulatory activity of pDCs was
independent of IFN-I or IL-12. PDCs acted in the lymph nodes during the sensitization phase
but were not required to directly prime T cells. Instead, pDCs depletion altered the ratio of
migratory cDC2:cDC1, leading to a more robust Th2 response and subsequent skin
inflammation. Further, lack of pDCs enhanced IRF4 levels in migratory DC subsets, inducing an
IRF4-dependent gene program that promoted differentiation of Th2-effector cells. Finally,
depletion of pDCs induced expansion of population of non-canonical DC that had a striking pDC
signature but appeared poised to prime Th2. These results support a model in which pDCs
impact CD4+T cell priming indirectly, by controlling the cDC subsets that are present in the
lymph node to prime T cells.

2.3 Results
2.3.1 pDCs suppress FITC- but not DNFB-induced CHS
This study was initially prompted by the observation that CLEC4C-DTR Tg mice treated with
DT developed noticeable skin inflammation when felt-tip markers were repeatedly used to mark
their tails (data not shown), suggesting that pDCs might control skin CHS. To directly test the
impact of pDCs on CHS, we performed CHS assays in CLEC4C-DTR Tg mice and wild-type
(WT) littermate controls using FITC and DNFB as haptens. These CHS models trigger Th2 and
Th1 CD4+ T cell responses, respectively26, 27, allowing us to determine whether pDCs inhibit Th1
or Th2 pathology uniquely, or are capable of generally inhibiting CHS through induction of T
regs or anergic T cells. Haptens were applied on the abdomen 5-6 days prior to challenge on the
ear (Figure 2.2a). Mice were administered DT every other day throughout the experiment,
resulting in >90% pDC depletion in the spleen and skin DLN on day 7 post-challenge in
CLEC4C-DTR Tg mice, while no depletion was observed in WT littermates (Figure 2.2b). In
the FITC model, pDC-depleted mice exhibited increased ear swelling and DLN cellularity 24

48

hours post challenge compared to non-depleted mice (Figure 2.1a,b). However, in the DNFB
model, we found no difference between pDC-depleted and non-depleted mice in either ear
swelling or DLN cellularity post challenge (Figure 2.1c,d). Histologic examination of FITC
challenged ears from pDC-depleted mice revealed markedly enhanced dermal edema,
granulocytic and lymphocytic infiltration, as well as epidermal crusting (Figure 2.1e,f).
Toluidine blue staining revealed mast cell hyperplasia in pDC-depleted mice (Figure 2.1g,h).
Microarray analysis of the FITC-challenged skin showed evidence of an enhanced type 2
immune response in pDC-depleted mice, with elevation of Il33, IL4ra, Fcer1g, Arg1, Arg2, and
Ptgs2 (Figure 2.1i). Pathway analysis showed enhanced lymphocyte and granulocyte infiltration,
keratinocyte activation and mast cell activation (Figure 2.1j). Concordantly, flow cytometric
analysis of the skin confirmed an increased amount of infiltrating CD45+ cells, dominated by
granulocytes in pDC-depleted mice (Figure 2.1c,d). The percentage of neutrophils of the CD45+
cells was significantly elevated in pDC-depleted mice with an additional trend towards an
increased percentage of eosinophils. CD11c+ cells were significantly decreased in the skin of
pDC-depleted mice (Figure 2.1d), which correlated with an increase in FITC+ CD11c+ cells in
the DLN post challenge (Figure 2.1e). Together, these data demonstrate that pDC depletion
results in an exacerbated CHS reaction to the FITC hapten, and suggest that pDCs can inhibit
Th2 driven pathology in the skin.

To confirm the suppressive effect of pDC on type 2 immunity in the skin, we performed a model
of atopic dermatitis driven by the vitamin D analog calcipotriol (MC903) (Figure 2.1f). Upon
application to the skin, calicipotriol acts to releave tonic transcriptional repression on the TSLP
locus, resulting in robust epidermal TSLP production which drives type 2 immunopathology28.
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CLEC4C-DTR Tg mice treated with this model for 21 days showed exacerbated gross pathology,
increased ear swelling and robust pathological changes to the skin including epidermal
thickening and architectural distortion (Figure 2.1g-i). These data corroborated the suppressive
role of pDC in type 2 allergic pathologies of the skin.

2.3.2 pDC depletion alters polarization of effector CD4+ T cells in FITC CHS
We sought to directly evaluate the effector T cell response underlying the exacerbated FITC
CHS. There was a significantly higher level of GATA3 expression within the entire CD4+ T cell
compartment in the DLN of pDC-depleted mice compared to non-depleted controls on day 7
(Figure 2.3a), as well as a higher percentage of GATA3+ cells within CD4+ T cells (Figure
2.3b), suggesting a bias towards Th2 responses. Assessment of cytokine production ex vivo in
the DLN revealed that whole lymph node cultures from pDC-depleted mice produced greater
amounts of IL-4 and IL-13, while those from non-depleted controls produced more IFN-γ
(Figure 2.3c-e). We further evaluated cytokine production on a per cell basis by intracellular
cytokine staining, which revealed that a higher percentage of CD4+ T cells from non-pDC
depleted mice made IFN-γ (Figure 2.3f,g), while the IFN-γ production from the CD8+ T cells
was similar in both depleted and non-depleted groups (Figure 2.4a,b). We also noted that a
slightly higher percentage of CD4+ and CD8+ T cells from pDC-depleted mice produced IL-17A
(Figure 2.3f,g and Figure 2.4a,b). Overall, these data indicated that pDC depletion biases T
cells responses towards Th2 and Th17 at the expense of Th1.

2.3.3 pDC depletion augments numbers and function of Tregs
Many studies that implicate pDCs in tolerance to allergens and other antigens have suggested
that pDCs act by inducing Tregs through a variety of mechanisms14, 18, 20, 29, 30. Thus, we assessed
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the frequency and number of Tregs in the DLN at day 7 in the FITC CHS model. We saw that
pDC-depleted mice actually had enhanced frequencies and numbers of Tregs (Figure 2.5a-c).
We also noted a significantly higher percentage of cells that expressed a subunit of the IL-33R,
ST2, within the Treg compartment (Figure 2.5a,d). ST2 signaling is known to induce elevate
Foxp3 levels in Tregs31, 32. Accordingly, Tregs in pDC-depleted mice appeared to express higher
levels of Foxp3 and GATA3 than did those in non-depleted controls (Figure 2.5e-h). Thus,
pDC-depletion is associated with an increased number of Tregs and enhanced Treg
responsiveness to IL-33, which may enhance their functions, as indicated by increased Foxp3
expression. This increase in Tregs is however insufficient to control CHS in pDC-depleted mice.

2.3.4 pDCs inhibit FITC CHS independently of IFN-I, IFN-λ and IL-12

It has been shown that IFN-I and pDC-produced IFN-I promote Th1 responses8, 33. Recent
studies have further demonstrated that IFN-I inhibits proliferation and survival of ILC2s, limiting
skin allergy34,
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. Moreover, pDC-produced IFN-I was shown to limit ILC2s in lung36,

37

.

Accordingly, we found that pDC-depleted mice had increased numbers and percentages of ILC2s
in the DLN after FITC challenge compared to non-depleted controls (Figure 2.6a-c). Thus, we
hypothesized that enhanced CHS in pDC-depleted mice was due to a deficit of IFN-I. To test this
hypothesis, we examined FITC CHS in Ifnar–/– compared to WT mice. Although Ifnar–/– mice
had increased numbers and percentages of ILC2s in the DLN after FITC challenge (Figure 2.6ac) as did pDC-depleted mice, ear swelling was similar in Ifnar–/– and WT mice (Figure 2.6d).
Thus, we concluded that reduction of pDC-derived IFN-I and consequent increase of ILC2s was
not sufficient to explain FITC CHS in pDC depleted mice. Because pDC also produce IFN-λ, we
evaluated the impact of IFN-λ on FITC CHS by examining mice that lack the receptor for IFN-λ,
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IL-28R. However, Il28ra–/– and WT mice were equally susceptible to FITC CHS, excluding the
possibility that pDC limit type 2 responses through IFN-λ (Figure 2.6d).

Since pDC or a cell subset within gated pDC can be a source of IL-128, 38, 39, we next examined
whether lack of IL-12 produced by pDCs might promote Th2 polarization and, consequently,
FITC CHS. To test this, we generated mice that lacked IL-12 selectively in pDCs but produced
IL-12 in other cell types by making mixed BM chimeras using CD45.2+ Il12p40–/– and
CD45.1+CD45.2+ CLEC4C-DTR Tg mice as BM donors and CD45.1+ WT mice as recipients
(Figure 2.7a). Upon administration of DT, >90% of the pDCs in these mixed BM chimeras
lacked IL-12p40 (Figure 2.7b). Control mixed BM chimeras were generated using CD45.2+
IL12p40–/– and CD45.1+CD45.2+ WT mice as BM donors. Upon induction of FITC CHS, similar
ear swelling was observed in all mixed BM chimeras, whether their pDCs did or did not produce
IL-12 (Figure 2.6e), indicating that pDC production of IL-12 has no detectable influence on
FITC CHS.

2.3.5 pDCs impact FITC CHS in the sensitization phase
The FITC-induced model of CHS encompasses priming and challenge phases. To evaluate the
impact of pDCs on each phase, we took advantage of the fact that DT transiently depletes pDCs
in CLEC4C-DTR Tg mice: pDCs disappear within 24 hours of DT administration and begin to
return between 48-72 hours after the last dose. Therefore, we depleted mice with either two
doses of DT on day -1 and 1, prior to FITC sensitization on the abdomen, or with one dose of DT
on day 5, prior to FITC challenge on the ear (Figure 2.9a). PDC depletion during the
sensitization phase was sufficient to exacerbate ear swelling at challenge (Figure 2.8a). Of note,
in mice depleted on day -1 and 1, pDCs had returned to WT levels by day 7 (Figure 2.9b). In
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contrast, when pDCs were depleted just prior to challenge, there was no effect on ear swelling
(Figure 2.8a). We concluded that pDCs inhibit the priming of Th2 response.

We next investigated whether pDCs could directly sensitize T cells to the hapten. When
examining the pool of FITC+ cells during the sensitization phase (days 1 and 2) we found little to
no contribution from pDCs. All of the FITChi cells in the DLN during this period were cDCs
(Figure 2.8b). Furthermore, pDCs in the DLN did not appear to upregulate activation markers
such as CD86 after FITC sensitization, whereas cDCs expressed high levels of CD86 (Figure
2.8b). The amount of FITC carried by cDCs in the skin DLN correlated with the expression of
CD86 (data not shown). Thus, it seemed unlikely that pDCs directly sensitize T cells to FITCantigens.

To further assess the impact of pDCs on the sensitization process, we examined the mRNA
expression profile of skin DLN one day after sensitization in pDC-depleted mice and WT
controls. In pDC-depleted mice, we saw upregulation of markers of type 2 inflammation, such as
Chi3l3 mRNA, together with Clec4a1 mRNA, which is highly expressed in CD4+ cDCs and
CD4–CD8–CD11b+ cDCs (www.immgen.org) (Figure 2.8c). In non-depleted control mice we
saw upregulation of the Klra17 (Ly49Q) mRNA, which is selectively expressed in pDCs, as well
as an increase in Cxcl9 mRNA, which are highly expressed in pDCs and CD8a+ cDCs in the skin
DLN (www.immgen.org) (Figure 2.8c). Together these data suggested that pDC depletion may
indirectly promote Th2 responses to FITC by altering the cDC subsets presenting haptens to T
cells.
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2.3.6 pDC depletion alters lymph node cDC subsets in steady state and CHS
The gene expression analysis of lymph nodes prompted us to evaluate the impact of pDC
depletion on the composition of cDCs in the skin DLN of pDC-depleted mice. We characterized
the CD11chiMHCIIint resident and CD11cintMHCIIhi migratory populations in the skin DLN at
steady state and during FITC sensitization. Within the resident cDCs, two subsets could be
identified using CD24 and Sirpa, corresponding to resident cDC1 and cDC2 respectively. Within
the migratory cDCs we could define four separate populations, CD103–CD326+ Langerin+ cells
(LC), CD103+ cDC1, and CD11b+ and triple negative (TN) cDC2, as previously described40, 41.
In the steady state, pDC depletion had no consequences on the resident cDC populations in skin
DLN or spleen (data not shown). However, in skin migratory cDC populations, we observed a
reduction in the frequency and number of CD103+ cDC1 and CD326+ LC, as well as an increase
in CD11b+ and TN cDC2 in pDC-depleted mice (Figure 2.11a,b). To ensure that this subset
skewing was due to a biological impact of pDC and not off-target expression of DTR in our
CLEC4C transgenic line, we assessed chimerism of various populations in CLEC4C-DTR Tg
CD45.1/2: WT CD45.2 mixed BM chimeras into CD45.1 hosts after DT administration (Figure
2.11c). Chimerism of pDC was >95% CD45.2, while chimerism of the other cDC populations
remained ~50% from each source, indicating that off-target expression of DTR is unlikely
(Figure 2.11d).

Forty-eight hours after FITC-sensitization, when cDC migration is peaking (Figure 2.10a), we
saw a similar subset skewing in pDC-depleted mice with significantly more migratory TN cDC2
and fewer CD103+ cDC1 in the inguinal and axillary lymph nodes (Figure 2.10b, c). This result
was confirmed with an additional gating strategy using Sirpa and CD24 within CD11cintMHCIIhi
cDCs to mark migratory cDC2 and cDC1, respectively. Here, pDC-depleted mice had
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significantly greater percentage of migratory Sirpa+ cDC2 and a corresponding decrease in the
percentage of CD24+ cDC1 (Figure 2.10d). Notably, the magnitude of cDC migration did not
seem to be altered, as the total number of migratory cDC in the DLN was not altered between
pDC-depleted and non-depleted mice (Figure 2.10e). Furthermore, we observed an increase in
the IRF4 expression within the entire migratory cDC subset in pDC-depleted mice, supporting
the skewing in the cDC2:cDC1 ratio (Figure 2.10f).

In addition to impacting the subsets making up the migratory cDC population, pDC depletion
seemed to increase the activation of migratory cDC. Upon examining the CD86 expression
within CD11cintMHCIIhi cDCs, we found it to be consistently higher in pDC-depleted mice
(Figure 2.10g). Interestingly, we did not see significant differences in the percentages of
Langerin+ cells in the epidermis or CD11b+ cDC2 or CD24+ cDC1 dermal DCs in pDC-depleted
mice during FITC sensitization41 (Figure 2.11e,f), indicating that pDCs likely do not impact skin
cDCs, but may influence their accumulation in the DLN.

2.3.7 Batf3–/– mice exhibit exacerbated FITC CHS
While we had established that migratory cDC subsets are altered in pDC-depleted mice, it was
unclear whether these changes can ultimately result in exacerbated Th2 driven CHS. To
determine if a decrease of migratory cDC1 could recapitulate the phenotype that we had
observed in pDC-depleted mice in the FITC CHS model, we utilized Batf3–/– mice on the
129SvEv background, which lack CD103+ CD24+ migratory cDCs, as well as corresponding
CD8a+ CD24+ resident cDCs. We observed that this mouse, like pDC-depleted animals,
exhibited enhanced contact hypersensitivity to FITC hapten compared to WT mice (Figure
2.10h). This result was corroborated by a previous report showing that Th2 production of IL-4 in
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response to FITC CHS is augmented in Batf3–/– mice compared to control mice40. Additionally,
it has previously been reported that in Batf3–/– mice DNFB CHS is comparable to that of WT
mice42, which is also the case in pDC-depleted mice. Thus, both Batf3–/– 129SvEv and pDCdepleted mice have enhanced responsiveness to Th2-driven FITC CHS, but do not exhibit
differential responsiveness to Th1-driven DNFB CHS. We conclude that pDC inhibit Th2driven CHS by maintaining an optimal ratio between migratory cDC1 and cDC2.

2.3.8 FITC sensitization does not affect the pDC transcriptome
To understand the mechanism(s) through which pDCs impact the cDC1:cDC2 balance in CHS,
we asked whether FITC sensitization modifies pDC phenotype and/or functions, such as
chemokine production. We sorted pDCs from skin DLN of mice, either untreated or 24h after
sensitization with FITC, and compared their transcriptomes by microarray analysis. Strikingly
few transcripts were differentially expressed by pDCs isolated from FITC-treated mice in
comparison to those from untreated mice (Figure 2.12a). We did investigate the possibility that
Camp could be acting as a chemotactic factor for CD103+ cDC1, however after substantial
investigation, we concluded that this was unlikely (discussed in the next section). These data
suggest that pDCs are not actually responding to FITC application, but regulate CHS through a
homeostatic mechanism. This hypothesis is consistent with our observation that pDC-depleted
mice harbor altered cDC subsets in the steady state (see Figure 2.11a,b). Thus, pDCs regulate
the balance of migrating cDC1:cDC2 during homeostasis and inflammation.

2.3.9 Camp is not necessary to drive cDC migration from skin to DLN in vivo.
Despite the largely absent response to FITC sensitization, we were intrigued to see that pDC
from treated mice had slightly upregulated Camp, which encodes the precursor to cathelicidin-
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related antimicrobial peptide (CRAMP), the homologue of human cathelicidin (also known as
LL37) (Figure 2.12a). Previous studies have shown that LL37 can complex with self nucleic
acids in psoriasis to promote type I interferon production by pDC43, 44. The possibility that pDC
may produce a molecule that in turn increases their activation was intriguing. Furthermore,
CRAMP can act in a chemotactic manner through binding to its receptor FPR2, expressed on
dendritic cells45. Therefore, we were interested in exploring if production of this molecule by
pDC could attract CD103+ and/or CD326+ migratory DC to the skin draining lymph nodes. We
first explored this possibility in vitro, through transwell migration assays. We generated bonemarrow derived CD103+ DC through prolonged culture with GM-CSF and FLT3L as previously
described46. We found that supernatant from stimulated bone-marrow derived pDC could attract
BM-derived CD103 DC (Figure 2.12b). Furthermore, recombinant CRAMP was capable of
inducing bone marrow derived CD103 DC migration in a dose dependent manner, as was a
chemical agonist of FPR2 (Figure 2.12b and data not shown).

While we determined that CRAMP had some capacity of attract CD103+ DC in vitro, it is
unclear if this would occur in vivo. Of note, one study demonstrated that FPR2-/- mice exhibit
reduced DC migration to the draining lymph node during allergic airway inflammation47, thus
the CRAMP-FPR2 axis seems to be necessary for dendritic cell migration under some stimuli.
Thus, we examined DC migration during FITC sensitization in Camp-/- mice. Surprisingly,
Camp-/- actually had enhanced migration of migratory CD326+ and CD11b+ subsets, and no
impact on the CD103+ subset (Figure 2.12c). Additionally, we generated mice that specifically
lacked Camp from pDC by generating mixed bone marrow chimeras with Camp-/- and CLEC4CDTR donors into WT recipients. Upon DT administration, these mice would only have pDC
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derived from Camp-/- mice, allowing us to assess the impact of CRAMP production by pDC
alone. These mice had similar migratory DC subsets to controls during FITC sensitization
(Figure 2.12d). Thus, we can conclude that Camp production by pDC does not impact cDC
migration during FITC CHS.

2.3.10 pDC impact the transcriptional profile of migratory cDC subsets
To further understand how pDCs might impact cDC subsets in vivo, we performed RNA-seq
analysis of migratory cDC subsets from pDC-depleted and non-depleted mice. Pooling 3-4 mice
per sample, we sorted and profiled CD103–CD326+Langerin+ DCs, CD11b+ cDC2, TN cDC2,
and CD103+ cDC1 (Figure 2.14a). Hierarchical clustering and principal component analysis
revealed that the migratory cDC subsets largely clustered according to their subset identity,
regardless of whether they came from pDC-depleted mice or littermate controls (Figure 2.13a,
b). We next filtered the data based on genes that were significantly differentially expressed
(p<0.05 after FDR correction; DESeq2) between pDC-depleted and non-depleted mice. The
results revealed robust transcriptional differences in the CD103+ subset, while relatively few
changes were evident in CD326+, CD11b+, and TN cells (Figure 2.14b, c). The expression of
genes for Th2-related molecules, MHCII antigen presentation, regulatory- and Th17-related
molecules weas enriched, while expression of Il18, Il15 and Ccl5 was diminished in the CD103+
subset from pDC-depleted mice (Figure 2.13c, 2.14d).

Notably, we observed that the CD103+ subset from pDC-depleted animals upregulated genes
dependent on IRF4, which has been reported to be important for the development and function of
cDC2s48,

49, 50, 51, 52

(Figure 2.13d). Gene set enrichment analysis (GSEA) confirmed

overrepresentation of two previously published sets of IRF4-dependent genes48, 53 in the CD103+
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and CD11b+ migratory cDCs from pDC-depleted mice (Figure 2.13e, 2.14e). Furthermore, we
confirmed that pDC-depleted mice had significantly increased IRF4 expression within CD326+,
CD11b+, and TN migratory cDC at steady state, with a trend towards increased IRF4 in the
CD103+ subset (Figure 2.13f,g). There was no change in IRF8 expression in CD103+ and
CD326+ migratory cDC and a slight reduction in IRF8 in CD11b+ and TN migratory cDC of
unclear significance (Figure 2.14f). Thus, in addition to increasing the migratory cDC2:cDC1
ratio, pDC-depletion biases the migratory cDC subset towards an IRF4-dependent phenotype,
probably reflecting the imprinting of a type 2 microenvironment.

2.3.11 Sc-RNA seq reveals vast changes in cDC clusters upon pDC depletion
To examine the impact of pDC depletion on skin DLN cDC populations with a non-biased
approach, we performed single cell RNA-seq analysis on resident and migratory cDC
populations from pDC-depleted and non-depleted mice 48 hours after FITC sensitization (gating
shown in (Figure 2.16a). Unsupervised clustering by tSNE identified 10 distinct DC populations
(Figure 2.15a). Expression of the DC lineage transcription factor Zbtb46 was uniform across
clusters (Figure 2.15b). Lack of expression of Fcgr1, Mertk, and Chi3l verified the absence of
macrophage or monocyte contamination (Figure 2.15b and Figure 2.16b). Based on differential
expression of key genes from the Immgen database, we identified migratory and resident cDC
populations. Genes such as Ccr7, Socs2, Fscn1, IL15ra, and IL15 were highly expressed by
migratory DCs. H2-Ob, Alox5ap, and Ciita were uniformly expressed in resident DCs (Figure
2.15b and Figure 2.16c,d).

We also distinguished cDC1 and cDC2 clusters within resident and migratory cDCs. Clusters 1
and 6, which mapped closely together, represented migratory cDC2 based on expression of
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Ccl22 and Ptger4 (Figure 2.15a,c, Figure 2.16e, Figure 2.18d). The highest expression of
Ccl17 was evident in cluster 1, along with an inflammatory phenotype delineated by Il1β and
NF-kB signaling molecules (Nfkbia, Nfkbiz, Tnaip3) (Figure 2.15c, Figure 2.16f, Figure 2.18e).
Transcripts of cluster 6 denoted the capacity for both Th2-skewing (Tnfsf4, Tnfrsf4, and Irf4) and
potent antigen presentation (CD86, H2-Dma, H2-Dmb1, CD74, H2-Aa, H2-Eb1, H2-Eb2)
(Figure 2.15c, Figure 2.16g, Figure 2.18f,g). Cluster 2 included bona fide migratory cDC1s
with expression of Irf8, B2m, and Tap1 (Figure 2.15c, Figure 2.16h, Figure 2.18i,j). Expression
of Cxcl16 and elevated expression of Ccr7 suggested that cluster 3 may contain Langerin+ cells
migrating from the epidermis (Figure 2.15b,c, Figure 2.16i, Figure 2.18k). Cluster 4 clearly
encompassed resident cDC2s, expressing Klf4, Sirpa, Mgl2, and Zeb2 (Figure 2.16j, Figure
2.18l), while cluster 5 contained resident cDC1s, expressing Xcr1, Clec9a, CD24a, Wdfy4, and
CD8a (Figure 2.15c, Figure 2.16k, Figure 2.18m). Cluster 0 expressed relatively few cluster
defining transcripts and could not be precisely classified, although it may correspond to TN DCs
(Extended data in Figure 2.18).

pDCs split into clusters 9 and 10 that were extremely similar transcriptionally: cluster 9 and 10
largely overlapped in gene expression and were enriched for genes involved in IFN-I production
and signaling (Irf7, Bst2, Tlr7, Ifnar2) (Figure 2.15c, Figure 2.16l, Figure 2.18n). Cluster 9
only expressed one unique cluster defining gene which it did not share with cluster 10, which
was Csf2rb. Surprisingly, cluster 9 also exhibited paradoxical expression of both Tcf4 and Id2,
indicating that may be in the process of losing pDC-associated gene programs (Figure 2.16m).
The genes unique to cluster 10 indicating that it may be cycling, and it was enriched by GSEA
analysis for G2M Checkpoint and Cell Cycle pathways (FDR< 2.60x10-6; FDR< 3.24x10-5).
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Cluster 8 resembled both previously described CD8α+ CX3CR1+ non-canonical DCs and recently
identified pDC-like cells2, 54, 55, 56 (Figure 2.15a-c, Figure 2.17). These cells have been reported
to be related to pDC, as they share a common gene signature, however they are more capable of
antigen presentation and less specialized in IFN-I production than the classical pDC. The CD8α+
CX3CR1+ non-canonical DC was also reported to have an overlapping gene prolife as cDC255.
Indeed, cluster 8 expressed many pDC-specific transcripts (Figure 2.15c, Figure 2.16l,m,
Figure 2.17c), but clustered closely to resident cDC2s and expressed several transcription factors
and receptors that designate cDC2 identity (Figure 2.15a, Figure 2.17a). Cd209a, CD209d,
CD209e, and Fcgrt were highly and specifically expressed by cluster 8 cells, suggesting that
these may be useful identifiers for pDC-like cells or CX3CR1+ non-canonical DCs (Figure
2.15e, Figure 2.17d).

Comparison of DCs from pDC-depleted and non-depleted DLN confirmed and extended our
flow cytometry data. pDC-depleted DLN had relatively more migratory cDC2s (cluster 1 and 6),
while non-depleted DLN were enriched in clusters 2 and 3 which correspond to migratory cDC1
and Langerin+ cells (Figure 2.15d). Among pDCs, cluster 10 was not completely ablated in the
CLEC4C-DTR Tg mice, suggesting incomplete expression of the CLEC4-DTR transgene in this
population (Figure 2.15d). Cluster 10 may represent cells that have recently exited the bone
marrow and retain a proliferation signature. Remarkably, CX3CR1+ non-canonical DCs (cluster
8) were enriched in CLEC4C-DTR Tg mice (Figure 2.15d), suggesting that depletion of mature
“classical DC” can facilitate the expansion of this related subset. We confirmed this expansion
in the skin DLN of pDC-depleted mice by flow cytometry, using CX3CR1, CD8a, and CD209a
as identifying markers (Figure 2.19a-d). We also confirmed protein expression of two other
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markers enriched in cluster 8 by the scRNAseq, CD48 and CD244 (2B4) (Figure 2.19e).

In

conclusion, scRNAseq analysis confirmed that pDCs regulate the composition of migratory
cDCs in the skin DLN during FITC sensitization and revealed more subtle alterations
unappreciated in the flow cytometry data, such as the expansion of non-canonical CX3CR1+
cDC when pDCs are reduced. Whether clusters 8, 9 or 10 are somehow related to the recently
identified pDC lymphoid progenitors56, 57 will be of interest in future studies. Ly6d, a proposed
marker of lymphoid derived DC was prominently expressed by both cluster 9 and 10 (Figure
2.17c), while Cx3cr1, Cd209e, and Cd14, proposed markers of myeloid derived DC, wer
expressed specifically by cluster 8 (Figure 2.15e, Figure 2.17d, Figure 2.18a). Notably, our
cluster 8 cells have expression of Cd8a (Figure 2.17b), while the pDC-like cells reportedly are
negative for this marker55.

2.4 Discussion
We were prompted to study pDCs in CHS by the observation that mice depleted of pDCs seemed
to develop marked skin inflammation after repeated staining of their tails with felt-tip markers.
To determine whether pDC depletion causes allergic skin reactions to innocuous antigens, we
tested different models of CHS and found that pDC depletion selectively exacerbated Th2-driven
CHS induced by FITC but not Th1-driven CHS induced by DNFB. Depletion of pDCs resulted
in increased frequency and numbers of GATA3+ CD4+ T cells as well as more IL-4 and IL-13 in
the lymph nodes, along with fewer Th1 cells and less IFN-g. These effects could not be
attributed to reduced levels of IFN-I or other Th1 polarizing cytokines resulting from pDC
depletion. Rather, depletion of pDCs affected sensitization phase of CHS by altering the ratio of
type2/type1-prone DCs in the DLN, priming CD4+ T cells towards a Th2 phenotype. Thus, pDCs
control the balance between cDC subsets that prime Th1 and Th2 responses.
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The impact of pDCs in functional polarization of Th responses has been controversial. An
original study reported that human pDCs induce Th2 responses7. In contrast, several subsequent
studies showed that pDCs attenuated Th2 responses in models of asthma14, 22, 30, skin allergy and
food allergy15. In these studies pDCs were shown to promote tolerance to allergens by inducing
Tregs. Our study confirms that pDCs limit priming of Th2 responses in a model of FITC-induced
CHS, but the mechanism is Treg independent. In fact, Treg numbers were paradoxically
increased in the lymph nodes of pDC-depleted mice with FITC-CHS; moreover, these Tregs
were potentially more responsive to IL-33, as indicated by heightened expression ST2, GATA3
and Foxp331, 32. Regardless, these changes in Tregs were insufficient to control the excessive Th2
response inititated after pDC depletion.

We excluded other expected alternative mechanisms by which pDCs could limit Th2. PDCs
secrete IFN-I, which promotes Th1 responses33 and has been shown to inhibit ILC2s34,

35

.

Consistent with a recent report36, pDC-depleted mice harbored increased numbers of ILC2s, as
did IFNAR-deficient mice. Yet, global lack of IFN-I signaling did not exacerbate FITC CHS.
Thus, although pDC-secreted IFN-I can limit ILC2 expansion, this is not sufficient to control
Th2 responses or CHS. A subset of pDCs has been shown to produce IL-12, which can bias T
cell functional polarization towards Th138, 39. However, the ability of pDCs to produce IL-12 did
not augment FITC CHS.

Rather, we demonstrated that pDC depletion alters the representation of distinct DC subsets that
migrate from the skin and prime T helper cells. Lymph nodes from mice depleted of pDCs
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during the sensitization phase had markedly reduced numbers of migratory CD103+ cDCs, which
induce Th1 responses58, 59, along with relative increased numbers of migratory CD11b+ cDCs that
induce Th2 and Th17 responses48, 50, 51, 52. The marked impact of pDC depletion on the cDC
composition in sensitized lymph nodes was further demonstrated by scRNA seq. Using this
unbiased technique we were able to demonstrate that, indeed, the migratory DC population was
skewed in pDC-depleted mice with an increase in the migratory DC2:DC1 ratio. Additionally,
we appreciated another alteration in the cDC compartment that was not observed by flow
cytometric methods. Specifically, we observed the expansion of cells corresponding to
previously described non-canonical CD8a+CX3CR1+ DC54,
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in addition to the recently

appreciated pDC-like cells56, which we believe may be related populations. These cells
reportedly share many features characteristic of pDCs, but are transcriptionally similar to cDC22,
54, 55

; this is substantiated in our study by the close clustering of CX3CR1+ non-canonical DCs

with resident cDC2s. We envision that pDC depletion facilitates the accumulation of Th2priming CX3CR1+ non-canonical DCs that differentiate from the same progenitor. Indeed, the
non-canonical CD8a+CX3CR1+ DC fails to develop in the absence of Tcf4, suggesting a
common progenitor with pDC. However, Rodrigues et al. have suggested that pDC-like and
classical pDC are derived from the common dendritic cell progenitor (CDP) and a lymphoid
progenitor (LP), respectively. Thus, it is also possible that these cells do not share a common
progenitor and depletion of classical pDC opens up a niche in peripheral lymphoid organs which
is filled with pDC-like cells. It will be important to establish how the pDC and non-canonical
DC subsets that we have identified in sensitized lymph nodes relate to the recently identified
pDC lymphoid progenitors in normal development56, 57.
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Altogether, these results support a new paradigm in which pDCs do not directly prime or
polarize CD4+T cells, but rather act indirectly by influencing the type of cDCs that prime CD4+T
cells. Consistent with this model, another study showed that during priming of antiviral T cell
responses in the lymph nodes, pDCs form superclusters with cDCs and CD8+T cells in which
pDCs enhance the capacity of cDC to stimulate CD8+T cells60. In data not shown here, we
excluded the possibility that pDCs selectively control migratory DC subsets through the
secretion of chemokines that preferentially attract CD103+ cDCs. In fact, we propose that pDCs
influence the environment of the interfollicular zone of the lymph node where DCs interact with
T cells, contributing to creating a niche that limits type 2 responses. The depletion of pDCs
facilitates the accumulation of migratory DC2s and CX3CR1+ DCs, biasing CD4+T cells towards
Th2. In conclusion, our data suggest that Th polarization in the lymph nodes depends on a
complex equilibrium that involves not only DC1s and DC2s, but also pDCs and pDC-related
cells. PDCs may have evolved to fine tune the adaptive immune response by enhancing Th1 and
Tc1 responses when faced with viral challenge and inhibiting maladaptive Th2 responses to noninfections antigens frequently encountered in the environment.

2.5 Methods
Mice. All animal studies were approved by the Washington University Institutional Animal Care
and Uses Committee. CLEC4C-DTR Tg male and female C57BL/6 mice (CD45.2 and CD45.1
CD45.2) were bred in house in a specific pathogen free facility. Littermate transgene negative
mice were used as controls for all experiments. CD45.1 male and female mice used as recipients
in bone marrow chimera studies were bred in house in a specific pathogen free facility. Female
Il12b–/– mice were purchased from The Jackson Laboratory (Bar Harbour, ME). Male and female
SvEv Batf3-/- mice were kindly provided by Brian Edelson and Ken Murphy (Washington
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University School of Medicine). Female Ifnar–/– mice were kindly provided by A. French
(Washington University School of Medicine). Female Il28ra–/– were kindly provided by M.
Diamond (Washington University School of Medicine).

All mice were used between 10-12

weeks of age.

CHS. In the FITC contact hypersensitivity protocol, mice were anesthetized with
ketamine/xylazine mixture and a 3 cm x 3 cm patch was shaved on the abdomen. 100µL of 0.5%
FITC solution dissolved in 1:1 mixture of acetone and dibutyl phthalate was applied
epicutaneously to the shaved skin on day 0 and day 2. On day 6, 20µL of 0.5% FITC solution
was applied to the right ear and 20µL of acetone/dibutyl phthalate solvent was applied to the left
ear. Ear swelling was measured 24 h later and mice were sacrificed for analysis. In the DNFB
contact hypersensitivity protocol, mice were anesthetized with ketamine/xylazine mixture and 1
cm x 1 cm patch was shaved on the abdomen. 20µL of 0.5% DNFB in a 4:1 mixture of acetone
and olive oil was applied epicutaneously to the shaved skin on day 0 and 1. On day 5, 20µL of
0.2% DNFB was applied to the right ear and 20µL of acetone/olive oil was applied to the left ear.
Ear swelling and analysis was conducted 24 h later. CLEC4C-DTR Tg mice and littermate
transgene negative WT controls were injected with 200-400ng of DT on day -1, 1, 3, and 5 in
both the FITC and DNFB CHS protocols, unless otherwise indicated.

Calcipotriol Skin Model. Calicipotriol (MC903) was applied topically to the right ear at a dose
of 2nmol every 2 days for 21 days. Ethanol was applied to the left ear as a solvent control. For
these experiments, CLEC4C-DTR Tg mice were injected with 200ng DT i.p. on days -1, 1, 3, 5,
and 7.
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BM Chimeras. BM from 8 wk old Il12b–/– mice (CD45.2) and CLEC4C-DTR Tg (CD45.1
CD45.2) was harvested from tibias and femurs. After RBC lysis, cells were counted and mixed at
a 1:1 ratio then injected into lethally irradiated (1100 rad) C57BL/6 mice (CD45.1). 3x106 cells
of each genotype were injected i.v. 24 h after irradiation. BM chimeras were subjected to the
FITC CHS protocol 8 wk after reconstitution.

Cell Preparations. Cell suspensions of spleen and LN were prepared by collagenase D digestion
and passage through nylon mesh cell strainers (BD Biosciences). BM was collected from tibias
and femurs. Red blood cells were lysed with RBC lysis buffer (Sigma-Aldrich). Serum was
prepared by collecting whole blood by cardiac puncture and centrifugation in serum separator
tubes (BD Bioscience). Cell suspensions of skin were prepared by Liberase TL digestion (Roche)
and passage through 70 micron nylon mesh cell strainers. For DC analysis of the skin, epidermis
was removed with dispase digestion and remain dermal layer was incubated in collagenase D and
passed through a 70 micron nylon mesh cell strainer after mincing. An additional passage
through a 40 micron cell strainer was performed immediately prior to staining for flow
cytometry.

Antibodies, Flow Cytometry and Sorting. The following reagents were from BD Biosciences,
eBioscience or Biolegend: fluorochrome labeled anti-CD45.1 (A20), anti-CD45.2 (104), antiCD45 (30-F11) anti-CD11c (HL3), anti-SiglecH (551 or 440c), anti-B220 (RA3-6B2), anti-CD4
(GK1.5), anti-CD8a (53-6.7), anti-CD3 (145-2C11), anti-CD11b (M1/70), anti-CD103 (2E7),
anti-CD172a (P84), anti-Siglec F (E50-2440), anti-Ly6G (1A8), anti-GATA3 (TWAJ), anti-
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FOXP3 (150D/E4), anti-IFNγ (XMG1.2), anti-IL17A (TC11-18H10), anti-CD127 (A7R34),
anti-ST2 (RMST2-2), anti-CD19 (1D3/CD19), anti-CD25 (PC61.5), anti-CD86 (GL1), anti-IA/I-E (M5/114.15), anti-CD326 (G8.8), anti-CD24 (M1/69), anti-NK1.1 (PK136) and anti-IRF4
(3E4). Fc receptors were blocked before surface staining and dead cells were excluded by
LiveDead Aqua stain (Life Technologies). For transcription factor detection, cells were stained
for surface markers followed by fixation and permeabilization with the Foxp3 staining buffer set
(eBioscience). Cells stained with intracellular antibodies diluted in 1× Perm Wash buffer
(eBioscience). For detection of intracellular cytokines, PMA/ionomycin stimulated cells and
controls were washed, surface stained, and fixed and permeabilized using Cytofix/Cytoperm
solution (BD Bioscience). Fixed cells were stained for intracellular cytokines with antibodies
diluted in 1 x Perm Wash solution (BD Bioscience). Stained cells were analyzed on a FACS
Canto with Diva software or on a FACS Calibur with CellQuest software. Flow cytometry data
was analyzed with FlowJo software (Tree Star, Inc.). Skin DLN from pDC from FITC treated
and untreated mice were sorted on a FACSAria II (BD Biosciences) after enrichment using a
negative selection microbeads kit, Plasmacyoid Dendritic Cell Isolation Kit (Miltenyi). For bulk
RNA-seq analysis of migratory DC population, cells were first enriched with CD11c Ultra pure
microbeads (Miltenyi) and then sorted into subsets on a FACSAria II (BD Biosciences). For
single cell RNAseq, cells were sorted without any enrichment on an FACSAria II (BD
Biosciences).

Cell Culture and Stimulations. Primary cells were cultured in complete RPMI 1640 with 10%
fetal calf serum (BCS), 1% glutamax, 1% nonessential amino acids, 1% sodium pyruvate, and
1% kanamycin sulfate (Gibco-Invitrogen). For secreted cytokine analysis, cells were cultured for

68

12h at 1 x 106 cells/mL with 10-7 M Phorbol 12-myristate 13-acetate (PMA) and 500ng/mL
ionomycin (Sigma). For intracellular cytokine staining, primary cells were cultured in complete
RPMI at 1 x 106 cells/mL with PMA/ionomycin for 6 hours with Brefeldin A (BD Biosciences)
added 2 hours into the culture. To generate pDC in vitro, C57BL/6 bone marrow cells were
cultured for 10 days with 1% FLT3L. At day 10, cells were harvested and pDC were isolated by
negative selection with CD19 microbeads followed by positive selection with B220 microbeads
(Miltenyi). pDCs were stimulated overnight with CpGA 2216 (6 mg/ml, Operon); CpGB 1826
(6 mg/ml, Operon) or Imiquimod (6 mM, InvivoGen). CD103+ DC were derived in vitro by
culture of C57BL/6 bone marrow in 2% FLT3L and 0.5% GM-CSF for 9 days. Cells were then
replated in fresh media and cultured for an additional 6-7 days.

ELISA and Cytometric Bead Array. Supernatants from lymph node cultures were collected
and stored at -20°C until analysis. IFN-γ and IL-4 were measured by cytometric bead array (BD
Biosciences). IL-13 levels were measured by ELISA (eBiosciences).

Microarray Analysis. RNA was prepared from whole lymph nodes or sorted DLN pDC
populations RNeasy Mini or Micro Kits (Qiagen). For whole lymph nodes, one mouse was used
per replicate and each replicate contained 5 x 106 cells. For DLN pDC, 3-4 mice were pooled
per replicate and each replicate contained at least 25,000 cells. Three replicates from each group
that passed quality control were amplified and hybridized to the Affymetrix Mouse Gene 1.0 ST
array (whole lymph node) or Affymetric Mouse Gene 2.0 ST (sorted pDC) by the Genome
Technology Access Center at Washington University, St. Louis, MO. For normalization, raw
data was processed by Robust Multi-Array (RMA) method. Pathway analysis was performed
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with GSEA software from the Broad Institute using MSigDB Hallmark and Canonical Pathways
gene sets (http://software.broadinstitute.org/gsea/index.jsp). Volcano plots and differential
expression analysis was performed using Multiplot studio and Morpheus with a threshold of 2
fold change and a minimum P value significance threshold of 0.05 (after False Discovery Rate
[FDR] correction for the number of tests). Microarray data has been deposited at GEO:

Migration Assay. Migration assays were performed using ChemoTx system 106-3 (3µm pore;
5.7mm diameter sites). 2 x 105 bone marrow derived CD103+ dendritic cells were loaded on the
top filter and 30µL of supernatant from bone marrow derived pDC or dilutions of CRAMP were
loaded into the bottom well. Migration chambers were incubated at 37°C for 2.5 h. Migration
was assessed by addition of Cell Titer Aqueous One Solution Reagent (Promega) to the bottom
well and incubation for 2 h at 37°C and subsequent absorbance reading using ELISA plate reader
at 490nm. Experimental wells were compared to a reference serial dilution to attain numbers of
cells migrated through the filter.

RNA Seq. RNA was extracted from freshly sorted migratory DC populations using RNeasy
Micro Kits (Qiagen). mRNA was enriched using RiboZero Gold kit (Illumina) which removes
28S, 18S, 5.8S and 5S RNA from solution. For cDNA synthesis, the Clontech SMARTer
Stranded RNA-seq kit, which uses a random priming method, was utilized. Libraries were
sequenced using a HiSeq 3000 (Illumina) with 1x50 single read sequencing runs. Sequence
reads were aligned to the reference genome using STAR61 and gene counts were derived from
uniquely aligned reads using Subread:featureCounts62. To identify significantly differentially
expressed genes, gene counts were imported in to R and analyzed with DeSeq263 (version 1.4.5)
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with default settings, and a minimum P value significance threshold of 0.05 (after False
Discovery Rate [FDR] correction for the number of tests). Hierarchecal clustering was done
with Morpheus using one minus pearson correlation with average linkage method. PCA was
performed in Phantasus. RNAseq data has been deposited at GEO:

Single cell RNA seq. Cells were sorted on an Aria II and preserved in 10% FCS RPMI until
input into 10X Genomics Single Cell Protocol. Isolated mouse cells were subjected to dropletbased 3’ end massively parallel single-cell RNA sequencing using Chromium Single Cell 3’
Reagent Kits as per manufacturer’s instructions (10x Genomics. The libraries were sequenced
using Illumina HiSeq4000 sequencers at the McDonnell Genome Institute. Sample
demultiplexing, barcode processing, and single-cell counting was performed using the Cell
Ranger Single-Cell Software Suite (10x Genomics). Cellranger count was used to align samples
to the reference genome (mm10), quantify reads, and filter reads with a quality score below 30.
The Seurat package in R was used for subsequent analysis64. Genes expressed in fewer than 3
cells and cells that expressed less than 400 or greater than 3500 genes were removed for
downstream analysis. Data was normalized using a scaling factor of 10,000, and nUMI was
regressed with a negative binomial model. Principal component analysis was performed using
the top 3000 most variable genes and t-SNE analysis was performed with the top 20 PCAs.
Clustering was performed using a resolution of 0.6. For identifying the markers for each cluster,
we performed differential expression of each cluster against all other clusters using MAST
package in R65, identifying negative and positive markers for that cluster. scRNAseq data has
been deposited at GEO:
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Statistical Analysis. The statistical significance of differences in mean values was analyzed with
unpaired, two-tailed Student’s t test. P values less than 0.05 were considered statistically
significant.
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Figure 2.1 pDC selectively suppress FITC induced CHS. CLEC4C-DTR Tg mice and WT
littermate controls were subjected to two different CHS models. For FITC CHS, FITC was
applied to the shaved abdomen on day 0 and day 2 (sensitization), and FITC was applied to the
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ear on day 6 (challenge). For DNFB CHS, 20µL of 0.5% DNFB was applied to the shaved
abdomen on day 0 and 1 (sensitization) and 20µL of 0.2% DNFB was applied to the ear on day 5
(challenge). DT was administered on day -1, 1, 3, and 5 in each model. a, Ear swelling measured
24h post challenge in the FITC treated ear (ipsilateral), and solvent treated ear (contralateral).
Data represents 3 pooled experiments (n=10 CLEC4C-DTR Tg+, n=12 Tg- littermate). b,
Cellularity of the ipsilateral ear DLN and contralateral DLN 24h post challenge with FITC.
Numbers reflect cell yield from 3 pooled superior cervical nodes digested with collagenase D.
Data represents 3 pooled experiments (n=10 CLEC4C-DTR Tg+, n=12 Tg- littermate). c, Ear
swelling measured 24h post challenge in the DNFB model. Data represents 3 pooled experiments
(n=8 CLEC4C-DTR Tg+, n=7 Tg- littermate). d, Ipsilateral DLN cellularity 24h post challenge
in the DNFB model. Numbers reflect cell yield from 3 pooled superior cervical nodes digested
with collagenase D. Data represents 3 pooled experiments (n=8 CLEC4C-DTR Tg+, n=7 Tglittermate). e, H&E histology of the ear pinna 24h post challenge with FITC at 10X
magnification. Epidermal crusting is indicated by the black arrow. Representative of 2
experiments (n=7 CLEC4C-DTR Tg+, n=7 Tg- littermate). f, Histological scoring of ear pinna
24h post challenge based on dermal edema, leukocyte infiltration, and epidermal crusting. Data
representative of 2 experiments (n=7 CLEC4C-DTR Tg+, n=7 Tg- littermate). f, Toluidine blue
staining 24h post challenge with FITC at 40X magnification. Data representative of 2
experiments (n=7 CLEC4C-DTR Tg+, n=7 Tg- littermate). h, Quantification of mast cells per
HPF at 40X via toluidine blue staining of the FITC treated ear 24h post challenge. Data
representative of 2 experiments, each data point represents an average of 15 HPF per sample
(n=7 CLEC4C-DTR Tg+, n=7 Tg- littermate). i, Volcano plot comparing gene expression by
microarray in ear skin one day post FITC challenge. Data represent fold change and p-value
calculated from 3 RNA samples per group; each sample is RNA derived from skin of one mouse
(n=3 CLEC4C-DTR Tg+, n=3 Tg- littermate). Transcripts in green or red indicate p < 0.05 and
fold change ≥ 2. j, Most highly significant pathways derived from GSEA (Broad) after input of
transcripts significantly increased in pDC-depleted mice (FC>2; p<0.05). *p<0.05, **p,0.01,
***p<0.001, ****p<0.0001; statistics by unpaired two tailed students T test. Data in a, b, c, d, f,
h are mean ± s.e.m. and each symbol represents an individual mouse.

74

Figure 2.2 pDC-depleted mice have enhanced pathology in a model of atopic dermatitis.
a, FITC and DNFB CHS and pDC depletion protocols. b, pDC depletion. Representative
staining of SiglecH+B220+ cells in the ipsilateral DLN and spleen 24h post FITC challenge.
Cells are gated on CD11cint. Representative of 8 separate experiments (n=28 CLEC4C-DTR
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Tg, n=29 Tg- littermates). c, Percent CD45+ cells isolated after 90 minute digestion of the ear
skin with Liberase TL and analysis by flow cytometry. Data pooled from 3 experiments (n=12
CLEC4C-DTR Tg, n=8 Tg- Littermates). d, Percent eosinophils (Siglec F+CD11b+CD11c–),
neutrophils (Ly6G+ CD11b+ CD11c–), or CD11c+ cells within the CD45+ gate in the digested
skin. Data pooled from 2 experiments (n=10 CLEC4C-DTR Tg, n=6 Tg- Littermates). e,
Percent CD11c+ FITC+ cells in the ipsilateral DLN 24h post challenge. Data pooled from 3
experiments (n=9 CLEC4C-DTR Tg, n=10 Tg- littermates). f, MC903 experimental design. g,
Gross appearance of ears from mice treated with protocol in (f). Representative of 2 experiments
(n=6 CLEC4C-DTR Tg, n=6 Tg- littermates). h, Ear swelling for first 7 days of protocol. Data
representative of 1 of 2 experiments (depicted: n=3 CLEC4C-DTR Tg, n=3 Tg- littermates, total;
n=6 CLEC4C-DTR Tg, n=6 Tg- littermates). i, H&E staining of pDC-depleted and non-depleted
mice treated with MC903. Representative of 2 experiments (n=6 CLEC4C-DTR Tg, n=6 Tglittermates). *p<0.05, **p,0.01, ***p<0.001, ****p<0.0001; statistics by unpaired two tailed
students T test. Data in c-e, h are mean ± st. dev. and each symbol representative of an individual
mouse.
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Figure 2.3 pDC depletion during FITC CHS increases Th2 polarization in DLN. Cells from
the ipsilateral superior cervical lymph nodes were isolated from CLEC4C-DTR Tg and littermate
control mice 24h post FITC challenge. a, Median fluorescence intensity of GATA3 in
CD4+CD3+ cells and b, percent GATA3+ of CD4+CD3+ cells. Data shows one experiment,
representative of 2 individual experiments (depicted: n= 6 CLEC4C-DTR Tg, n=6 Tglittermates; total: n= 12 CLEC4C-DTR Tg, n=12 Tg- littermates). c-e, Cells from DLN were
stimulated with PMA/ionomycin for 12h at a concentration of 1x106 cells/mL and supernatants
were analyzed for cytokine concentrations by CBA (IFN-γ and IL-4) or ELISA (IL-13). Data in c
pooled from 2 experiments (n=5 CLEC4C-DTR Tg, n=5 Tg- littermates). Data in d pooled from
2 experiments (n=7 CLEC4C-DTR Tg, n=7 Tg- littermates). Data in e pooled from 2
experiments (n=7 CLEC4C-DTR tg, n=7 Tg- littermates). Each data point reflects the mean of 2
technical replicates from the same sample. Each sample is derived from one mouse. f,
Representative staining of intracellular cytokine staining (ICS) of CD4+ cells after stimulation
with PMA/ionomycin for 6h with Brefeldin A and Monensin in culture for the final 4h. g,
Quantification of the percentage of IFN-γ+ or IL-17A+ cells within the CD4+CD3+ population.
Data is representative of 1 of 2 experiments (depicted: n= 5 CLEC4C-DTR Tg, n=6 Tg77

littermates; total: n=10 CLEC4C-DTR tg, n=10 Tg- littermates). *p<0.05, **p,0.01,
***p<0.001, ****p<0.0001; statistics by unpaired two tailed students T test. Data in a, b, c, d, e,
g are mean ± st. dev. and each symbol represents an individual mouse.

Figure 2.4 CD8+ T cells are largely unaffected by pDC depletion in FITC CHS a,
Intracellular cytokine staining of CD8+ T cells stimulated with PMA/ionomycin. b,
Quantification of IFN-γ+ and IL-17A+ cells within the CD8+ CD3+ population. Data is
representative of 1 of 2 experiments (depicted: n=5 CLEC4C-DTR tg, n=6 Tg- littermates, total:
n=10 CLEC4C-DTR tg, n=10 Tg- littermates). *p<0.05, **p,0.01, ***p<0.001, ****p<0.0001;
statistics by unpaired two tailed students T test. Data in b are mean ± st. dev. and each symbol
represents an individual mouse.
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Figure 2.5 pDC depletion enhances Treg in FITC CHS. Cells from the ipsilateral superior
cervical lymph nodes were isolated from CLEC4C-DTR Tg and littermate control mice 24h post
FITC challenge. a, Representative Treg staining, gated on CD4+CD3+ cells, and representative
ST2 staining, gated on FoxP3+CD25+CD4+CD3+ cells. b and c, Percent of FoxP3+CD25+ of
CD4+CD3+ and number of FoxP3+CD25+CD4+CD3+ cells per lymph node. Data is pooled from 3
experiments (n=10 CLEC4C-DTR Tg, n=11 Tg- littermates). d, Percent ST2+ cells of
FoxP3+CD25+CD4+CD3+ cells. Data is pooled from 3 experiments (n=10 CLEC4CDTR-Tg,
n=11 Tg- littermates). e, Representative staining of FoxP3 and GATA3 within CD4+CD3+ cells.
f, Median fluorescence intensity of FoxP3 within FoxP3+CD25+CD4+CD3+ cells and
ST2+FoxP3+CD25+CD4+CD3+ cells. Data is pooled from 3 experiments (n=10 CLEC4CDTRTg, n=11 Tg- littermates). g, Percent of FoxP3+GATA3+ cells within CD4+CD3+ cells. h, Mean
fluorescence intensity of GATA3 within FoxP3+CD4+CD3+ cells. Data from g, h is
representative of 1 of 2 individual experiments (depicted: n= 6 CLEC4C-DTR Tg, n=6 Tglittermates ; total: n= 9 CLEC4C-DTR Tg, n=9 Tg- littermates). *p<0.05, **p,0.01, ***p<0.001,
****p<0.0001; statistics by unpaired two tailed students T test. Data in b, c, d, f, g and h are
mean ± st. dev. and each symbol represents an individual mouse.
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Figure 2.6 pDC do not suppress FITC CHS through IFN-I, IFN-l, or IL-12. a,
Representative ILC2 staining from ipsilateral DLN 24h post FITC challenge, gated on
CD127+CD3–CD19– cells. b, Percent GATA3+ST2+ of CD127+CD3–CD19– cells within the
ipsilateral DLN 24h post FITC challenge and c, number of CD3–CD19–CD127+GATA3+ST2+
cells. Data in a-c represent 2 pooled experiments (n=10 CLEC4C-DTR Tg, n=10 Tg- littermates,
n=3 Ifnar–/–). d, Ifnar–/–and Il28ra–/– mice were treated with the FITC CHS protocol along with
CLEC4C-DTR and WT mice as controls. All mice were administered DT. Ear swelling
measured 24h post challenge in the FITC treated ear. Data represents 2 pooled experiments (n=5
CLEC4C-DTR Tg, n=7 Tg- littermates, n=5 Ifnar–/–, n=8 IL28ra–/–). e, CD45.1+ WT mice were
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irradiated with 1100 rad and reconstituted with a 50-50 mixture of either CLEC4C-DTR Tg
CD45.1+CD45.2+ plus IL12p40–/–CD45.2+ or WT CD45.1+CD45.2+ BM plus IL12p40–/–CD45.2+
BM. 8 weeks after reconstitution, mice were subjected to the FITC CHS protocol with DT given
day -1, 1, 3 and 5. Ear swelling measured 24h post challenge in the FITC treated ear. Data
represents 2 pooled experiments (n=8 WT:Il12–/– chimeras, n=6 CLEC4C-DTR Tg:Il12–/–
chimeras) *p<0.05, **p,0.01, ***p<0.001, ****p<0.0001; statistics by unpaired two tailed
students T test. Data in b-e are mean ± st. dev. and each symbol represents an individual mouse.
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Figure 2.7 Generation of CLEC4C-DTR:Il12-/- bone marrow chimeras result in mice that
lack IL-12 producing pDC. a, Experimental design. b, Representative percentages of CD45.2+
(Il12p40–/–), CD45.1+CD45.2+ (CLEC4C-DTR Tg or WT) and CD45.1+ (recipient) cells in the
B220+ and the SiglecH+B220+CD11cint populations within the spleen on day 7, 24h after FITC
challenge. Data representative of 2 experiments (n=8 WT:Il12–/– chimeras, n=6 CLEC4C-DTR
Tg:Il12–/– chimeras). Data in b are mean ± st. dev. and each symbol represents an individual
mouse.
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Figure 2.8 pDC suppress FITC CHS during the sensitization phase but do not carry hapten
to the DLN. a, Mice were administered a modified FITC CHS protocol with DT administered on
day -1 and 1 (D-1 + D1 depletion) or administered on day 5 (D5 depletion). Ear swelling was
measured 24h post challenge in the FITC treated ear. Data is pooled from 3 experiments (n=8
CLEC4C-DTR+ Tg, n=7 Tg- littermates, n=10 D-1 and D1 depleted CLEC4C-DTR+ Tg, n=5
D5 depleted CLEC4C-DTR+ Tg). b, Representative FITC positivity and CD86 staining 24h or
48h post sensitization (red, in SiglecH–CD11c+ cells or CD11cintB220intSiglecH+ cells compared
to an untreated mouse (blue). Data is representative of 3 separate experiments (n=9 untreated
mice; n=9 FITC treated mice). c, Volcano plot comparing gene expression in pooled inguinal and
axillary LN one day post FITC sensitization in pDC-depleted and non-depleted mice. Data
represent fold change and p-value calculated from 3 RNA samples per group; each sample is
RNA derived from inguinal and axillary LN of one mouse (n=3 CLEC4C-DTR Tg+, n=3 Tglittermate). Transcripts in red or green indicate a fold change ≥ 1.5 and p < 0.10. *p<0.05,
**p,0.01, ***p<0.001, ****p<0.0001; statistics by students T test. Data in a are mean ± st. dev.
and each symbol represents an individual mouse.
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Figure 2.9 CLEC4C-DTR mice allow for transient depletion and subsequent recovery of
pDC. a, Experimental design. b, Representative staining of SiglecH+B220+CD11cint cells in the
spleen 24h post FITC challenge. Cells are gated on CD11cint. The “pDC depleted: Sensitization”
group are CLEC4C-DTR Tg mice given DT on day -1 and 1; the “pDC depleted: Challenge”
group are CLEC4C-DTR Tg mice given DT on day 5; the “CLEC4C-DTR Tg” and “littermate
control” groups were given DT on day -1, 1, 3, and 5. Data is representative of 3 experiments
(n=8 CLEC4C-DTR+ Tg, n=7 Tg- littermates, n=10 D-1 and D1 depleted CLEC4C-DTR+ Tg,
n=5 D5 depleted CLEC4C-DTR+ Tg).
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Figure 2.10 PDC-depleted mice have more migratory cDC2 and fewer migratory cDC1 in
skin DLN. a, Number of migratory DC (CD11cintMHCIIhi) subsets in inguinal and axillary LN at
baseline (0) and 24, 48, and 72h after epicutaneous FITC application. Data is representative of 1
of 2 experiments (depicted: n= 3 mice per time point, total: n=7 WT mice per time point). b,
Representative flow plot for migratory and resident DC populations in the axillary and inguinal
lymph node 48 hours post FITC sensitization. Cells pregated on live, FSChi SSChi. c,d,
Percentages and e, numbers of indicated migratory DC populations. Data represents 1 of 3
experiments (depicted: n=3 CLEC4C-DTR Tg, n=3 Tg- littermates; total: n=12 CLEC4C-DTR
Tg, n=12 Tg- littermates). f, Mean fluorescence intensity (MFI, of IRF4 in migratory DC
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(MHChiCD11cInt) in inguinal and axillary lymph nodes. Data is pooled 2 separate experiments
(n=9 CLEC4C-DTR Tg, n=9 Tg- littermates). g, MFI of CD86 in migratory DC. Data pooled
from 2 separate experiments (0h: n=4 CLEC4C-DTR Tg, n=6 Tg- littermates, 24h: n=8
CLEC4C-DTR Tg, n=9 Tg- littermates, 48h: n=8 CLEC4C-DTR Tg, n=8 Tg- littermates, and
72h n=5 CLEC4C-DTR Tg, n=6 Tg- littermates). h, Ear swelling after FITC CHS protocol was
performed in Batf3–/– and WT controls on the 129SvEv background. Data is pooled from 3
separate experiments (n=8 Batf3–/–, n=7 WT 129SvEv). *p<0.05, **p,0.01, ***p<0.001,
****p<0.0001; statistics by unpaired two tailed students T test. Data in a, c-h are mean ± st. dev.
and each symbol represents an individual mouse.
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Figure 2.11 PDC-depletion alters the migratory cDC compartment at steady state, but not
because of off-target depletion. a, Frequency and b, number of migratory DC subsets in pDCdepleted and non-depleted mice at steady state (no treatment). Data is representative of 1 of 2
separate experiments (depicted: n=3 CLEC4C-DTR+ Tg, n=3 Tg- littermates, total: n=8
CLEC4C-DTR+ Tg, n=8 Tg- littermates). c, Experimental scheme depicting generation of BM
chimeras. d, CD45.1 mice were irradiated at 1100 rad and given a mixture of BM from
CLEC4C-DTR Tg CD45.1/2 and B6 CD45.2 donors. Mice were given 2 doses of DT, and
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chimerism in the indicated cell subsets was analyzed. Data are representative of 1 of 3
experiements (depicted: n=3 CLEC4C-DTR Tg CD45.1/2:B6 CD45.2 chimeras; total n=9
CLEC4C-DTR Tg CD45.1/2:B6 CD45.2 chimeras). e,f, Indicated cell frequencies in the
epidermis and dermis after FITC sensitization. Data pooled from 2 experiments (n=4 CLEC4CDTR Tg, n=5 Tg- littermates). *p<0.05, **p,0.01, ***p<0.001, ****p<0.0001; statistics by
unpaired two tailed students T test. Data in a, b, d-g are mean ± st. dev. and in e-g each symbol
represents an individual mouse.
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Figure 2.12 Camp production by pDC does not mediate cDC1 migration to the skin DLN. a,
Volcano plot of microarray data comparing pDC sorted from skin DLN of FITC sensitized mice
and untreated mice. Data represent fold change and p-value calculated from 3 RNA samples per
group; each sample is RNA derived from sorted pDC pooled from 5-7 mice (n=3 FITC
sensitized, n=3 untreated). Transcripts in green or red indicate p < 0.05 and fold change ≥ 2. b,
Left: FLT3L derived DC were sorted to obtain B220+ CD19- bone marrow derived pDC and
stimulated for 18h with CpGA, CpGB, or 27601 (TLR7 agonist). CD103 cells were derived
from bone marrow cultures of FLT3L + GM-CSF (iCD103) and migration towards supernatant
from stimulated B220+ (pDC) cell populations was assessed by transwell assay. Right: iCD103
migration toward CRAMP peptide was assessed by transwell assay. c, DC numbers and percents
in skin DLN of Camp-/- and WT 48h post FITC sensitization (n=5 Camp-/-, n=5 B6 cohoused
mice). d, Bone marrow chimeras with CLEC4C-DTR animals and Camp-/- as in Figure 2.7a.
(depicted: n=3 CLEC4C-DTR:Camp-/- chimeras, n=3 CLEC4C-DTR:WT chimeras, total: n=6
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CLEC4C-DTR:Camp-/- chimeras, n=6 CLEC4C-DTR:WT chimeras) *p<0.05, **p,0.01,
***p<0.001, ****p<0.0001; statistics by students T test.
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Figure 2.13. Migratory cDC from pDC-depleted mice have an IRF4 signature. Cells from
the cervical, inguinal, and axillary lymph nodes were isolated from CLEC4C-DTR Tg and
littermate control mice 48h post FITC sensitization on the abdomen and ears. DC were enriched
using Militenyi Ultra pure CD11c microbeads and subsets were sorted for RNA extraction (n=3
CLEC4C-DTR Tg, n=3 Tg- littermates, each RNA sample is pooled from sorted cells from 3-4
mice). a, b, Hierarchical clustering analysis and PCA from migratory DC subsets from pDCdepleted and non-depleted mice. c, Heat maps of selected DEGs (FC>2, FDR<0.05) from the
CD103+ subset. d, Heat map of IRF4 regulated genes selected from previous publications48, 53.
Heat map on left depicts FPKM values, heat map on the right depicts log2 fold change values
(pDC-depleted/non-depleted), *FDR<0.05, **FDR<0.01, ***FDR<0.001, ****FDR<0.0001. e,
GSEA plots of top 12,000 expressed genes ranked by t statistic, with genes enriched in pDCdepleted mice ranked first. GSEA plot uses IRF4-dependent genes identified in Gao, et al.48. f,
Histograms of IRF4 expression in the indicated subset at steady state after 2 doses of DT 48
hours apart (representative of n=6 CLEC4C-DTR Tg, n=6 Tg- littermates). g, MFI of IRF4 in
the indicated subset of migratory DC, representative of 1 of 2 experiments (depicted: n=3
CLEC4C-DTR Tg, n=3 Tg- littermates, total: n=6 CLEC4C-DTR Tg, n=6 Tg- littermates).
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Figure 2.14 Transcriptional changes in migratory cDC from pDC-depleted mice are largely
confined to the CD103+ subset. a, Sorting strategy for migratory DC subsets. G1=CD326+
(Langerin+ cells), G2=CD11b+ (migratory cDC2), G3=TN (migratory cDC2), G4=CD103+
(migratory cDC1). b, Venn diagram of DEGs (Fold change>2, FDR<0.05) in the indicated
subsets up-regulated in non-depleted and pDC-depleted mice. c, DEGs from CD11b, TN, and
CD326 migratory DC (Fold change>2, FDR<0.05). Heat maps depict log2 FPKM values. d,
Heat maps of selected DEGs (FC>2, FDR<0.05) from the CD103+ subset. e, GSEA plots of top
12,000 expressed genes ranked by t statistic, with genes enriched in pDC-depleted mice ranked
first. GSEA plot uses IRF4-dependent genes identified in Vander Lugt, et al.53. f, MFI of IRF8 in
MHCIIhi CD11cint cells and the indicated migratory DC subsets isolated from the steady state
lymph nodes after 2 doses of DT 48h apart. Representative of 1 of 2 experiments (depicted: n=3
CLEC4C-DTR Tg, n=3 Tg- littermates, total: n=6 CLEC4C-DTR Tg, n=6 Tg- littermates).
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Figure 2.15 scRNAseq of migratory populations in pDC-depleted and non-depleted mice
reveals subset skewing. DC from inguinal and axillary LN from FITC treated mice were sorted
48h after application and submitted for single cell RNAseq via the 10X Genomics platform.
2165 cells were analyzed from pDC depleted mice, with a median of 9852.5 UMIs and 2170.5
genes per cell. 3312 cells were analyzed from non-depleted mice, with a median of 9135 UMIs
and 1996 genes per cell. a, tSNE plot revealing DC clusters. b, Heat map tSNE showing gene
expression of representative genes revealing DC (Zbtb46), resident DC (H2-Ob), migratory DC
(Ccr7), pDC (Siglech) and monocyte (Fcrγ1) populations. c, Table containing top 10-15 most
significant cluster-defining genes (by p value) per cluster shown in (a) obtained comparing mean
gene expression of each cluster against all other clusters. d, tSNE plot and cluster frequency of
total DCs for pDC-depleted and non-depleted mice. e, Heat map tSNE gene expression of
CX3CR1 and violin plot of Cd209d.
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Figure 2.16 scRNA sequencing allows for identification of DC lineages. a, Sorting strategy
for DC isolated from axillary and inguinal lymph nodes of pDC-depleted and non-depleted mice
48h post FITC sensitization for scRNAseq. Cells in G1 and G2 were pooled for analysis, and
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cells in G1 were capped at 5% of the total sorted cells. b, Heat map tSNE for genes
representative of monocyte/macrophages. c, Heat map tSNE for genes highly expressed by
migratory DC. d, Heat map tSNE for genes highly expressed by resident DC. e, Heat map tSNE
of genes expressed highly by cDC2. f, Heat map tSNE of representative genes highly expressed
by cluster 1. g, Heat map tSNE of representative genes highly expressed by cluster 6. h, Heat
map of genes highly expressed by cluster 2. i, Heat map tSNE of Cxcl16. j, Heat map of
representative genes highly expressed by cluster 4. k, Heat map tSNE of representative genes
highly expressed by cluster 5. l, Heat map tSNE of representative genes highly expressed by
cluster 10. m, Violin plots of Id2 and Tcf4 expression across clusters.
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Figure 2.17 Cluster 8 shares a gene signature with cDC2 and pDC. Heat map tSNE for genes
expressed by cluster 8 cells and DC2. b, Heat map tSNE for genes highly expressed cluster 8
cells and DC1, or only by DC1. c, Heat map tSNE for genes highly expressed by cluster 8 cells
and pDC. d, Heat map tSNE of genes expressed uniquely by cluster 8 cells.
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Figure 2.18 Extended expression analysis of skin DLN DC clusters. Heat map tSNE plots for
genes indicative of a, monocyte/macrophage contamination, b, migratory cDC (Immgen), c,
resident cDC (Immgen), d, Cluster 1 and 6 mig cDC2, e, Cluster 1 mig cDC2 f, MHCII antigen
presentation g, Th2 priming DC h, Langerin/mig cDC1 (Immgen) i, MHCI antigen presentation
j, Mig cDC1 signature k, Langerin cells l, Resident cDC2 m, Resident cDC1 n, pDC/IFN-I
interferon signature
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Figure 2.19 Cluster 8 cells can be identified by flow cytometry using CX3CR1 and CD209a.
a, Heat map tSNEs demonstrating enriched transcripts for Cd8a, Cx3cr1, and Cd209a in cluster
8. b, Identification of cluster 8 by flow cytometry. c, Cluster frequencies of total sorted cells. d,
Quantification of cluster 8 frequency in skin DLN and spleen after 2 doses of DT 48h apart. e,
Confirmation of Cd48 and Cd244 expression by flow cytometry.
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Chapter 3

Discussion and Future Directions: Mechanisms by
which pDC suppress type 2 immunity
Hannah Miller
Department of Pathology and Immunology, Washington University School of Medicine

3.1 Summary
In order to better understand how pDC impact type 2 immune responses, we have examined the
role of pDC during FITC contact hypersensitivity, a model of allergic contact dermatitis known
to be driven by Th2 cells, as it is dependent on STAT6, IL-4 and CD4 T cells1. Upon performing
this model in CLEC4C-DTR mice, we consistently observed that pDC-depleted mice exhibit
exacerbated contact hypersensitivity.

We quantified this phenotype by calculating the ear

swelling, scoring histological sections of the skin, as well as quantifying immune infiltration into
the skin by flow cytometry. By each measure, pDC-depleted mice showed enhanced disease.
Furthermore, we characterized the polarization of CD4+ and CD8+ T cells during this model. We
consistently show by intracellular cytokine staining, transcription factor staining, and ELISA for
secreted cytokine that pDC-depleted mice have greater Th2/Th17 polarization and decreased Th1
polarization in this model, while cytokine production by CD8+ T cells was unaffected. In stark
contrast to other studies that show pDC induce tolerance via induction of Tregs, pDC-depleted
mice had elevated Tregs, with increased expression of ST2, GATA3, and FOXP3, suggesting
enhanced functional capacity.
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We have also shown through differential administration of diphtheria toxin that pDC inhibit
FITC-CHS during the sensitization phase, during which naïve T cells are being polarized to
various effectors. Furthermore, analysis of our model in Ifnar-/- mice, Il28ra-/- mice, as well as
mixed bone marrow chimeras of CLEC4C-DTR and Il12b-/-, in which specifically pDC lack IL12p40, demonstrated that pDC are not inhibiting allergic CHS through production of type I
interferons, type III interferons, nor IL-12p40. Moreover, by examining the FITC+ cells in the
DLN during sensitization, we can conclude that cDC and not pDC are carrying haptenated
antigens or upregulating costimulatory molecules such as CD86.

With the evidence that pDC were acting during the sensitization phase of the model, we carefully
characterized the immune populations in the skin DLN after initial FITC application. We
demonstrated that in the absence of pDC, the migratory cDC compartment in the skin DLN was
drastically altered, including a reduction of CD103+ DC and CD326+ DC and an increase in Th2polarizating CD11b+ and triple negative fractions. This finding was present during steady state
as well as during inflammation. Furthermore, we noted that many IRF4-dependent genes were
up-regulated in the migratory CD103+ cDC1 and migratory CD11b+ cDC2 from our pDCdepleted animals. In fact, GSEA (gene set enrichment analysis) revealed that genes previously
reported to be dependent on IRF4 in bone marrow derived DC were enriched in both of these
populations from pDC-depleted mice. Additionally, pDC-depleted mice had enhanced levels of
IRF4 protein in CD326+, CD11b+ and TN migratory DC subsets at steady state.
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Next, we performed scRNAseq of dendritic cell populations in pDC-depleted mice. Because DC
and macrophage/monocyte populations can change their expression of cell surface markers
during inflammation, it was important to ascertain whether changes we saw in the cDC
compartment in the setting of pDC-depletion reflect true diversity and population shift.
Strikingly, when evaluating dendritic cells in the skin DLN, we were able to appreciate 10
distinct populations of cells corresponding to 3 populations of pDC, 2 populations of resident
DC, and 5 populations of migratory dendritic cells. The shift within the migratory population
from cDC1 to cDC2 in pDC-depleted mice was confirmed, while the ratio of cDC1 and cDC2 in
the resident compartment was not dependent on the presence of pDC. Most intriguingly, we
were able to appreciate new diversity within the pDC compartment. Two population of pDC
seemed especially primed to produce IFN-I. These populations had substantial overlap in the
cluster defining genes, with the exception of cell cycle genes confined to one of the cluster,
indicating it may be actively cycling and giving rise to the other cluster. Finally, a third
population was actually expanded in the CLEC4C-DTR mice.

This population resembled

previously described populations of “non-canonical” DC9,10 and pDC-like cells14 that express
CX3CR1 and have features of cDC2 by transcriptional analysis. We hypothesize that this
population could account for some of the CD4+ T cell alterations that we see in pDC-depleted
mice.

3.2 Mechanisms of pDC-mediated suppression of allergic contact
hypersensitivity
At this time, it is still somewhat unclear how exactly pDC are acting to inhibit Th2-drive contact
hypersensitivity. However, there are three potential mechanisms that our data suggest, which are
not mutually exclusive. First, the major inhibitory mechanism by which pDC act in the FITC
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CHS model may be by facilitating CD103+ cDC1 migration to or retention within the skin DLN.
This idea is supported by our own data showing that Batf3-/- mice, which lack cDC1, phenocopy
the pDC-depleted mice in the FITC-CHS model. Furthermore, it has been shown that Batf3-/mice are less susceptible to Heligmosomoides polygyrus infections due to enhanced Th2
immunity2. Our data demonstrates that CD103+ cDC1 do migrate to the DLN after epicutaneous
FITC application, which may suggest they participate in the immune response rather than acting
as bystanders. Interestingly, they seem to have slightly delayed migration kinetics compared to
migratory cDC2 (shown in Figure 2.10a). These migratory cDC1 may directly inhibit Th2
polarization through secretion of IL-12, as was demonstrated in the helminth infection model, or
perhaps simply serve to limit cDC2 migration by filling a niche in the lymph node.

Next, pDC may suppress type 2 immunity by suppressing the transcriptional activity of IRF4 in
migratory cDC. Dendritic cell expression of IRF4 has been reported to be important in the
generation of type 2 adaptive immunity3,4, but it is unclear if IRF4+ DC are directly and
singularly required for Th2 priming. IRF4 is required for the development of a subset of cDC2,
as conditional deletion of Irf4 in dendritic cells using Itgax-Cre results in a reduction of CD11b+
cells in the lung and of CD11b+ CD103+ in the small intestine lamina propria5,6. These mice also
have some defects in cDC2 in the skin DLN, but do not appear to have reduced cDC2 in the
dermis, suggesting a role for IRF4 in migration to the DLN rather than development of these
dermal cells3. In fact, at most mucosal sites IRF4 seems to promote DC migration to the
draining nodes, as cDC2 are also greatly reduced in the mediastinal and mesenteric nodes of
conditional IRF4 knock out mice driven by Itgax-Cre.
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While it is unclear if IRF4-dependent cDC are directly responsible for the priming of Th2 cells,
it is evident that IRF4 expression in cDC can enhance type 2 responses by multiple mechanisms
including, 1) inducing expression of Ccl17 and Ccl22 which can attract previously primed
CCR4+ Th2 cells3, 2) inducing expression of IL10 and IL33 which may help with polarization of
naïve T cells to Th2 effectors4, and 3) by regulating migration to the draining lymph node7.
Additionally, it has been shown that IRF4 directly binds target genes involved in MHCII
processing and presentation including Ctss, H2-Oa, and H2-Dmb2 which mediate peptide
loading in the MHCII binding pocket and facilitate the removal of invariant chain. Increased
expression of IRF4 in cDC2 of pDC-depleted mice may enhance type 2 immune responses and
Th2 priming through any of these mechanisms. In macrophages, IRF4 can negatively regulate
TLR4 signaling and inhibit the production of inflammation cytokines such as IL-6, IL-12p40,
and TNFα8. If IRF4 functions in a similar way in DC, migratory cDC from pDC-depleted mice
may produce fewer Th1 polarizing cytokines, promoting Th2 skewing.

How pDC may inhibit IRF4 expression in migratory DC is unclear at this time. It has been
shown that Th2-inducing stimuli such as HDM can induce IRF4 in dendritic cells4. In fact, in
our model of FITC CHS, we see a large increase in the MFI of IRF4 in all subsets of migratory
DC compared to homeostatic conditions.

It has also been shown in vitro that FcrγRIII can

induce IRF4 in bone marrow derived DC (BMDC)4, and TGFβ can inhibit the generation of
IRF4-dependent PDL2+ cells (although it is unclear if this is due to direct inhibition of IRF4
itself)3. Therefore, it is possible that absence of pDC may enhance innate inflammation to Th2inducing stimuli, or pDC may be making something that directly inhibits IRF4 expression such
as TGFβ. Interestingly, pDC do make a significant amount of TGFβ1 at rest in skin DLN, along
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with resident CD4+ and CD8a+ DC (www.immgen.org). The relative contribution that pDC
make to the amount of TGFβ in the skin DLN is not known.

Finally, it is entirely possible that the subset skewing and transcriptional alteration of the
migratory DC subset is not solely responsible for the Th2-suppressing capacity of pDC. Instead,
the expansion of the non-canonical DC cluster (cluster 8; Figure 2.15a) could be facilitating
enhanced Th2 priming, such that the suppression of type 2 immunity is actually achieved
through a homeostatic balance between pDC and this non-canonical subset, which is perturbed
with pDC-depletion via the CLEC4C-DTR mouse. This non-canonical subset of DC is very
intriguing, as it has an overlapping gene expression profile with both cDC2 and pDC. There has
been evidence of such a cell since 2010 in the literature (termed non-canonical CD8α+CX3CR1+
DC)9,10, however recently with the advances in single cell RNA sequencing technology, similar
subsets have been described in the human (termed AS DC)11–13 and mouse (termed pDC-like
cells)14,15. Together these cells share common functional features, with differing degrees of
impairment in IFN-I production and enhanced ability to stimulate CD4+ T cells, relative to
classical pDC (Figure 3.1). There is conflicting data on their ability to produce IL12p70; the
Axl+ Siglec6+ (AS) DC has a subpopulation of cells that can produce IL-12p7011, while the
originally described CD8α+CX3CR1+ DC does not produce IL-12p70, but can make IL-12p40,
suggesting IL-23 production9. The IL-12p70 producing ability of the pDC-like mouse subset
described in Rodrigues et al. was not assessed. Notably, in the mouse, the CD8α+CX3CR1+ noncanonical DC and the pDC-like cells have been proposed to originate from different precursors.
The CD8α+CX3CR1+ DC subset is TCF4 dependent and harbors Igh chain rearrangements,
indicative of a shared precursor with classical pDC9. On the other hand, the pDC-like cells have
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been proposed to represent pDC that derived from the CDP, with all “classical” pDC deriving
from lymphoid progenitors in this model14. Regardless of their origin, the cells that we found to
be expanded in pDC-depleted mice, which we will refer to in this chapter as cDC2-like pDC,
share overlapping features with both of these mouse populations, as well as with AS population
of human DC (summarized in Table 3.1). It is possible that this is due to these cells sharing a
common precursor with classical pDC, such with classical pDC depletion, the precursor cells are
expanded to compensate and as a result generate cDC2-like pDC.

Alternatively, perhaps

classical pDC and cDC2-like pDC occupy the same niche in the periphery, and deletion of the
classical pDC causes the pDC-like cDC2 to expand to fill the void. Why the classical pDC are
depleted in the CLEC4C-DTR mice and cDC2-like cells are not is a mystery. It may be related
to insufficient expression of E2-2 to drive activity at the CLEC4C promoter, as the reports of the
human population show that these cells have decreased expression of Tcf411,12, although this does
not appear to be universal to the mouse cells. While the expansion of the cDC2-like pDC is
substantial in the pDC depleted mice, this population still only represents about 6% of the total
DC population, so its relative contribution compared to other DC populations to Th2 priming
remains unclear. Indeed, studies have shown that KLF4+ TN DC carry the majority of the FITC
hapten to the skin DLN during sensitization, and these cells are also essential for pathology in a
house dust mite driven asthma model and anti-helminth responses to Schistosoma mansoni16.
Interestingly, the cDC2-like pDC also express KLF4, indicating a potential role for these cells in
the previously observed phenotypes (Table 3.1).

3.3 Caveats and Future Directions
Caveats to this study revolve mainly around the use of CLEC4C-DTR mouse as a model to
investigate pDC function. While this strain arguably represents the best available method to
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efficiently deplete pDC without side effects on other cell types, our study reveals a previously
unappreciated expansion of cDC2-like pDC in CLEC4C-DTR mice, which is potentially a
confounding variable in investigating the functional role of classical pDC. In the future, it will
be essential to understand the developmental relationship between classical pDC and the pDClike cDC2/pDC-like/CD8α+CX3CR1+ non-canonical DC, in addition to understanding the
relationship between the different pDC-related subsets and whether they actually represent the
same cell type (Figure 3.1). This may allow for techniques to better target one subset of pDC
over the other, or target both subsets at the same time. Importantly, our study suggests that the
CLEC4C-DTR mouse may actually be an efficient strategy for targeting the classical pDC while
preserving the pDC-related cells.

There may also be concerns as to whether acute depletion of pDC is reflective of a physiologic
scenario, or whether acute removal of a cell population may have effects that extend beyond the
normal physiologic function of that cell type. Our lab has previously observed that pDC undergo
substantial apoptosis after viral infection in an IFN-I dependent manner; therefore, it is likely
that pDC undergo activation-induced death in many inflammatory scenarios in which IFN-I is
involved. Furthermore, we have demonstrated that germ-free mice have reduced pDC in the
periphery17, suggesting that alterations in the microbiome could impact peripheral pDC
frequencies, perhaps acutely, as pDC have a relatively short lifespan18. Thus, acute depletion of
pDC may not be an uncommon scenario in biology. This may also be a contributing factor to
development of post-viral type 2 immunopathology. Virus induces IFN-I, which results in pDC
apoptosis. This may not have a detrimental impact on the course of the viral infection as other
cells can compensate for the loss of IFN-I producing capacity of pDC; however, this acute

118

depletion of pDC may relieve tonic suppression on type 2 immunity, either through loss of Treg
generation as previous studies have shown20 or through the alteration of the cDC compartment as
our study suggests. It will be interesting to expand our findings from the FITC CHS model to a
model of post-viral immunopathology, to evaluate if the alterations of the cDC compartment
with pDC-depletion play a role in other scenarios in which more robust inflammation is present.
Finally, DT administration has been shown to have effects on dendritic cells and lymph node
morphology regardless of the DTR transgene status19. To minimize DT as a confounder in our
studies, we always use DTR transgene negative littermates as controls, which are administered
DT alongside the DTR positive mice.

3.4 An emerging paradigm: pDC inhibit Th2 immunity
With our contribution to the vast and contradictory literature on the involvement of pDC in type
2 immune responses, a paradigm emerges in which pDC can inhibit Th2 effector cells via
multiple mechanisms. During viral infection or induction of IFN-I, pDC may limit subsequent
immunopathology that can develop through generation of Tregs, perhaps via Sema4a
production20. Since many pDC undergo apoptosis in response to IFN-I, this may be mediated by
a distinct subset of pDC that do not make IFN-I themselves, or by a population more resistant to
interferon signaling. Furthermore, pDC may be capable of inhibiting ILC2 proliferation and
cytokine production through IFN-I, as it has been shown that ILC2 are negatively regulated by
IFN-I21,22. Additionally, one study demonstrated that pDC-depletion abrogated the suppressive
effect of a TLR7 agonist on IL-33 induced ILC2 cytokine responses23. Our also suggests that
pDC control ILC2 in an IFN-I dependent manner. It remains to be determined whether this
represents a mechanism by which pDC inhibit type 2 immunity within a physiologic disease
model. Additionally, in some selective viruses where pDC are important for early control, such
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as rodent specific pneumovirus (PVM), dampening of viral propagation at the epithelium can
limit the release the alarmin IL-33 from infected cells, thereby potentially limiting the
proliferation and cytokine production by ILC220,24.

In the absence of viral infection, pDC are capable of limiting type 2 immune responses to
innocuous antigens. pDC have been shown to induce tolerance to OVA-induced asthma in
multiple studies, primarily through induction of Tregs through an unclear mechanism that may
involve production of retinoic acid25 or expression of PDL126. Additionally our study reveals a
potentially new mechanism by which pDC prevent type 2 immune responses at steady state, by
promoting a balance of Th1-priming cDC1 and Th2-priming cDC2 and cDC2-like pDC. Why
allergic individuals generate an immune response to environmental antigens remains a mystery
within the field of immunology. Our data suggests that a balance of dendritic cell subsets in skin
DLN, which serve as sensors for the vast number of antigens we encounter on a daily basis, is
essential to prevent inappropriate activation of the immune system to generally harmless
substances. Indeed, our first observation in this project was that pDC-depleted mice developed
atopic lesions in response to ink from a permanent marker applied to the skin. Thus, any
perturbation in the pDC population, whether via IFN-I induced apoptosis or perturbations in the
microbiome that impact pDC trafficking to the periphery, could skew the skin DLN DC subsets
and predispose to the development of type 2 immunopathology. Likewise, pDC may suppress
the immune response to helminths, which has implications for understanding the immune
responses of the many people in the world coinfected with viruses and worms. In conclusion,
our study adds to the emerging paradigm that pDC are important players in limiting pathologic
type 2 immunity.
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Plbd1
Fcgrt
Il13ra1

Non-canonical DC
Cx3cr1+ CD8a+

Irf4
Cd209a
S100a6
Ifitm3
Ccr1

Cluster 10
Apex1
Slc35c2
Cdh1
Gpr146
Atp2b4
Cd72
Pim2

Tlr7
Pacsin1
Sla2
Mzb1
Ptprs
Ogt
Ncf1b
Mpeg1
Csf2rb

Tlr7
Slc15a4
Pacsin1
Sla2
Mzb1
Traf4
Tmed2
Tm9sf2
Tacc1
Ssr4
Slc38a1
Seplg
CD48
CD209a
CD209d

Scarb2
Ptprs
Ppp1r14b
Ogt
Nrp1
Ncf1b
Mpeg1
Man2b1
Higd1a
Gpm6b
Cirbp

Pltp
Cox6a2
Siglech
Ly6d
CCR9
Tlr7
Cybb

Dntt
Mzb1
Irf8
Klk1
Pacsin1

Ifitm2
CD300a
CD200r1
CD48
CD209d
CD209a
CD209e
CD33

Rodriguez et al., 2018
PDC
SIGLECH+ BST2+
Zbtb46Bar-On et al., 2010

Cluster 9
Ifi30
Ifitm3
Aldh2
Dpsyl2
Irf4
Sep6
Ccnd3
Bin1
Gpr146

Ccr2
Csf1r
Ifitm3
Cyp4f16
Cd8a

Pltp
Cox6a2
Siglech
Ly6d
CCR9
Tlr7
Cybb

Dntt
Mzb1
Irf8
Klk1
Pacsin1

Table 3.1 Similarities between cluster 8 cDC2-like pDC and other published subsets of
pDC-related cells. Shown is the overlapping gene expression between cluster 8 (cDC2-like
pDC), cluster 9 (classical pDC), and cluster 10 (classical pDC) identified in our dataset with
other published gene signatures. Genes that were expressed equivalently in all three clusters are
not listed.
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Figure 3.1 Diversity of pDC and pDC-related cells in mouse and human Antigen presenting
cells that have pDC features have been identified in the human and mouse (human AS DC11,12;
mouse non-canonical CX3CR1+ CD8α+9,10; mouse pDC-like cells14). The cluster 8 cells
identified in this study may be related to these cell types based transcriptomic analysis. These
observations suggest that a population of pDC specialized in IFN-I production exists. Markers in
parentheses are suggested by transcript levels but have not been confirmed by protein staining.
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